PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
34356479-7	2021	Azithromycin combinations with either linezolid, ceftriaxone, gentamicin, or cefotaxime provided synergy in 42.1%, 44.7%, 31.6% and 7.9% of the 38 MAC-MRSA isolates, respectively.	Cefotaxime	77-87	solute carrier family 9 member A6	Homo sapiens	151-155
2129029-0	1990	Nasal carriage of MRSA: the role of mupirocin and outlook for resistance.	Mupirocin	36-45	solute carrier family 9 member A6	Homo sapiens	18-22
2129029-3	1990	During an MRSA outbreak at a London hospital, standard infection control measures failed to prevent colonisation and infection of more than two hundred patients, but the use of mupirocin was associated with epidemiological control.	Mupirocin	177-186	solute carrier family 9 member A6	Homo sapiens	10-14
34356479-0	2021	Association of Macrolide Resistance Genotypes and Synergistic Antibiotic Combinations for Combating Macrolide-Resistant MRSA Recovered from Hospitalized Patients.	Macrolides	15-24	solute carrier family 9 member A6	Homo sapiens	120-124
33300825-10	2021	The most informative approach targeted solely fluoroquinolones, reporting improvements in relevant Pseudomonas susceptibilities and MRSA, but without sufficient data on other effects of the strategy to assess its overall utility in clinical practice.	Fluoroquinolones	46-62	solute carrier family 9 member A6	Homo sapiens	132-136
34791706-7	2022	CONCLUSIONS: Our finding extends the catalog of pathogenic intronic variants affecting SLC9A6 pre-mRNA splicing and provides a basis for the genetic diagnosis of CS.	Cesium	162-164	solute carrier family 9 member A6	Homo sapiens	87-93
34718190-0	2021	Distribution of erm genes among MRSA isolates with resistance to clindamycin in a Chinese teaching hospital.	Clindamycin	65-76	solute carrier family 9 member A6	Homo sapiens	32-36
34718190-1	2021	The objective of this study was to analyze erythromycin and clindamycin resistance patterns among different MRSA lineages in China.	Erythromycin	43-55	solute carrier family 9 member A6	Homo sapiens	108-112
34718190-1	2021	The objective of this study was to analyze erythromycin and clindamycin resistance patterns among different MRSA lineages in China.	Clindamycin	60-71	solute carrier family 9 member A6	Homo sapiens	108-112
34718190-4	2021	Additionally, 88.2% (60/68) of the ST59 MRSA isolates and 78.9% (15/19) of the ST239 MRSA isolates had constitutive resistance to clindamycin, while 82.0% (123/150) of the ST5 MRSA isolates showed inducible clindamycin resistance.	Clindamycin	130-141	solute carrier family 9 member A6	Homo sapiens	40-44
34718190-4	2021	Additionally, 88.2% (60/68) of the ST59 MRSA isolates and 78.9% (15/19) of the ST239 MRSA isolates had constitutive resistance to clindamycin, while 82.0% (123/150) of the ST5 MRSA isolates showed inducible clindamycin resistance.	Clindamycin	130-141	solute carrier family 9 member A6	Homo sapiens	85-89
34718190-4	2021	Additionally, 88.2% (60/68) of the ST59 MRSA isolates and 78.9% (15/19) of the ST239 MRSA isolates had constitutive resistance to clindamycin, while 82.0% (123/150) of the ST5 MRSA isolates showed inducible clindamycin resistance.	Clindamycin	207-218	solute carrier family 9 member A6	Homo sapiens	176-180
34718190-8	2021	Summarily, high erythromycin and clindamycin resistance rates were observed in MRSA isolates.	Erythromycin	16-28	solute carrier family 9 member A6	Homo sapiens	79-83
34718190-8	2021	Summarily, high erythromycin and clindamycin resistance rates were observed in MRSA isolates.	Clindamycin	33-44	solute carrier family 9 member A6	Homo sapiens	79-83
34718190-11	2021	Erythromycin and clindamycin resistance genes transfer between MRSA isolates in healthcare settings remains a problem, and infection control procedures should be applied.	Erythromycin	0-12	solute carrier family 9 member A6	Homo sapiens	63-67
34718190-11	2021	Erythromycin and clindamycin resistance genes transfer between MRSA isolates in healthcare settings remains a problem, and infection control procedures should be applied.	Clindamycin	17-28	solute carrier family 9 member A6	Homo sapiens	63-67
34153574-0	2021	Design, synthesis and biological evaluation of pleuromutilin-Schiff base hybrids as potent anti-MRSA agents in vitro and in vivo.	pleuromutilin	47-60	solute carrier family 9 member A6	Homo sapiens	96-100
34153574-0	2021	Design, synthesis and biological evaluation of pleuromutilin-Schiff base hybrids as potent anti-MRSA agents in vitro and in vivo.	Schiff Bases	61-72	solute carrier family 9 member A6	Homo sapiens	96-100
34153574-3	2021	Among these derivatives, compound 60 exhibited superior in vitro antibacterial effect against MRSA (MIC = 0.25 mug/mL) than tiamulin (MIC = 0.5 mug/mL), and compound 60 (-2.28 log10 CFU/mL) also displayed superior in vivo antibacterial efficacy than tiamulin (-1.40 log10 CFU/mL) in reducing MRSA load in the mouse thigh infection model.	tiamulin	124-132	solute carrier family 9 member A6	Homo sapiens	292-296
34153574-3	2021	Among these derivatives, compound 60 exhibited superior in vitro antibacterial effect against MRSA (MIC = 0.25 mug/mL) than tiamulin (MIC = 0.5 mug/mL), and compound 60 (-2.28 log10 CFU/mL) also displayed superior in vivo antibacterial efficacy than tiamulin (-1.40 log10 CFU/mL) in reducing MRSA load in the mouse thigh infection model.	tiamulin	250-258	solute carrier family 9 member A6	Homo sapiens	292-296
34880951-1	2021	Background: Periprosthetic infection is commonly caused by Staphylococcus aureus and, if resistant to methicillin (MRSA), is associated with increase in severity and costs to patient and healthcare systems.	Methicillin	102-113	solute carrier family 9 member A6	Homo sapiens	115-119
34278512-0	2021	Correction to: Natural brominated phenoxyphenols kill persistent and biofilm-incorporated cells of MRSA and other pathogenic bacteria.	phenoxyphenols	34-48	solute carrier family 9 member A6	Homo sapiens	99-103
34356479-7	2021	Azithromycin combinations with either linezolid, ceftriaxone, gentamicin, or cefotaxime provided synergy in 42.1%, 44.7%, 31.6% and 7.9% of the 38 MAC-MRSA isolates, respectively.	Gentamicins	62-72	solute carrier family 9 member A6	Homo sapiens	151-155
34356479-0	2021	Association of Macrolide Resistance Genotypes and Synergistic Antibiotic Combinations for Combating Macrolide-Resistant MRSA Recovered from Hospitalized Patients.	Macrolides	100-109	solute carrier family 9 member A6	Homo sapiens	120-124
34356479-1	2021	Macrolide-resistant methicillin-resistant Staphylococcus aureus (MAC-MRSA) is one of the most clinically relevant pathogens due to its significant ability of resistance acquisition to different antimicrobial agents.	Macrolides	0-9	solute carrier family 9 member A6	Homo sapiens	69-73
34356479-9	2021	In conclusion, azithromycin combinations with either linezolid, or ceftriaxone showed synergism in most of the MAC-resistant MRSA clinical isolates.	Azithromycin	15-27	solute carrier family 9 member A6	Homo sapiens	125-129
34356479-1	2021	Macrolide-resistant methicillin-resistant Staphylococcus aureus (MAC-MRSA) is one of the most clinically relevant pathogens due to its significant ability of resistance acquisition to different antimicrobial agents.	Methicillin	20-31	solute carrier family 9 member A6	Homo sapiens	69-73
34356479-9	2021	In conclusion, azithromycin combinations with either linezolid, or ceftriaxone showed synergism in most of the MAC-resistant MRSA clinical isolates.	Linezolid	53-62	solute carrier family 9 member A6	Homo sapiens	125-129
34356479-7	2021	Azithromycin combinations with either linezolid, ceftriaxone, gentamicin, or cefotaxime provided synergy in 42.1%, 44.7%, 31.6% and 7.9% of the 38 MAC-MRSA isolates, respectively.	Azithromycin	0-12	solute carrier family 9 member A6	Homo sapiens	151-155
34356479-9	2021	In conclusion, azithromycin combinations with either linezolid, or ceftriaxone showed synergism in most of the MAC-resistant MRSA clinical isolates.	Ceftriaxone	67-78	solute carrier family 9 member A6	Homo sapiens	125-129
34356479-7	2021	Azithromycin combinations with either linezolid, ceftriaxone, gentamicin, or cefotaxime provided synergy in 42.1%, 44.7%, 31.6% and 7.9% of the 38 MAC-MRSA isolates, respectively.	Linezolid	38-47	solute carrier family 9 member A6	Homo sapiens	151-155
34356479-9	2021	In conclusion, azithromycin combinations with either linezolid, or ceftriaxone showed synergism in most of the MAC-resistant MRSA clinical isolates.	mac	111-114	solute carrier family 9 member A6	Homo sapiens	125-129
34356479-7	2021	Azithromycin combinations with either linezolid, ceftriaxone, gentamicin, or cefotaxime provided synergy in 42.1%, 44.7%, 31.6% and 7.9% of the 38 MAC-MRSA isolates, respectively.	Ceftriaxone	49-60	solute carrier family 9 member A6	Homo sapiens	151-155
34150881-1	2021	Spread of livestock-associated methicillin resistant Staphylococcus aureus (LA-MRSA) to farmworkers has been recognized as a risk when working in LA-MRSA positive stables, due to LA-MRSA being present on airborne dust particles.	Methicillin	31-42	solute carrier family 9 member A6	Homo sapiens	79-83
34201722-3	2021	A secondary objective was to describe the rate of favorable clinical response in patients with bloodstream infections (BSI) due to methicillin-resistant Staphylococcus aureus (MRSA-BSI) receiving ceftaroline.	Methicillin	131-142	solute carrier family 9 member A6	Homo sapiens	176-180
34201722-3	2021	A secondary objective was to describe the rate of favorable clinical response in patients with bloodstream infections (BSI) due to methicillin-resistant Staphylococcus aureus (MRSA-BSI) receiving ceftaroline.	T 91825	196-207	solute carrier family 9 member A6	Homo sapiens	176-180
34201722-7	2021	Among patients with MRSA-BSI, ceftaroline was used as a first-line therapy and salvage therapy in 25% (3/12) and 75% (9/12) of cases, respectively, and as a monotherapy or in combination with daptomycin in 58% (7/12) and 42% (5/12) of patients, respectively.	T 91825	30-41	solute carrier family 9 member A6	Homo sapiens	20-24
34201722-10	2021	The use of ceftaroline for MRSA-BSI, either as a monotherapy or in combination with other anti-MRSA agents, showed promising rates of favorable response.	T 91825	11-22	solute carrier family 9 member A6	Homo sapiens	27-31
34201722-10	2021	The use of ceftaroline for MRSA-BSI, either as a monotherapy or in combination with other anti-MRSA agents, showed promising rates of favorable response.	T 91825	11-22	solute carrier family 9 member A6	Homo sapiens	95-99
34150881-1	2021	Spread of livestock-associated methicillin resistant Staphylococcus aureus (LA-MRSA) to farmworkers has been recognized as a risk when working in LA-MRSA positive stables, due to LA-MRSA being present on airborne dust particles.	Methicillin	31-42	solute carrier family 9 member A6	Homo sapiens	149-153
34150881-1	2021	Spread of livestock-associated methicillin resistant Staphylococcus aureus (LA-MRSA) to farmworkers has been recognized as a risk when working in LA-MRSA positive stables, due to LA-MRSA being present on airborne dust particles.	Methicillin	31-42	solute carrier family 9 member A6	Homo sapiens	182-186
35378374-6	2022	Therefore, we hypothesized that ketamine lowers the endosomal pH by reducing the endosomal NHE6 protein level, and this hyperacidification promotes the amyloidogenic pathway.	Ketamine	32-40	solute carrier family 9 member A6	Homo sapiens	91-95
35624517-0	2022	Synthesis of new 2-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-ylimino)thiazolidin-4-one derivatives as anti-MRSA and anti-H. pylori agents.	2-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-ylimino)thiazolidin-4-one	17-86	solute carrier family 9 member A6	Homo sapiens	107-111
35378374-8	2022	Western blotting results showed that 100 mg/kg ketamine treatment in vivo and 1000 muM ketamine treatment in vitro increased endosomal BACE1 and CTF-beta protein levels and reduced endosomal NHE6 and APP protein levels.	Ketamine	47-55	solute carrier family 9 member A6	Homo sapiens	191-195
35378374-8	2022	Western blotting results showed that 100 mg/kg ketamine treatment in vivo and 1000 muM ketamine treatment in vitro increased endosomal BACE1 and CTF-beta protein levels and reduced endosomal NHE6 and APP protein levels.	Ketamine	87-95	solute carrier family 9 member A6	Homo sapiens	191-195
35378374-12	2022	Monensin did not affect amyloidogenic-related proteins or NHE6 directly; therefore, ketamine-promoted endosomal amyloidogenic processing and BACE1 accumulation were depleted by restoring endosomal acidity through monensin pretreatment.	Ketamine	84-92	solute carrier family 9 member A6	Homo sapiens	58-62
35378374-13	2022	Finally, knockdown of NHE6 promoted the amyloidogenic pathway similarly and prevented further enhancement by ketamine.	Ketamine	109-117	solute carrier family 9 member A6	Homo sapiens	22-26
35378374-14	2022	These results indicated that the effects of ketamine on the amyloidogenic pathway were dependent on the reduction of NHE6 and endosomal pH.	Ketamine	44-52	solute carrier family 9 member A6	Homo sapiens	117-121
3266621-1	1988	Methicillin and gentamicin resistant strains of Staphylococcus aureus (MRSA) remains a cause of significant morbidity and mortality.	Methicillin	0-11	solute carrier family 9 member A6	Homo sapiens	71-75
35198730-6	2022	Results: The missense variation (c.265T>C, p.Trp89Arg) in SLC9A6 cosegregated with atypical parkinsonism and intellectual disability in female carriers of this family.	trp89arg	45-53	solute carrier family 9 member A6	Homo sapiens	58-64
2687368-5	1989	For patients infected with MRSA, vancomycin is the drug of choice.	Vancomycin	33-43	solute carrier family 9 member A6	Homo sapiens	27-31
35007085-0	2022	Secondary Amine Pendant beta-Peptide Polymers Displaying Potent Antibacterial Activity and Promising Therapeutic Potential in Treating MRSA-Induced Wound Infections and Keratitis.	amine pendant beta-peptide polymers	10-45	solute carrier family 9 member A6	Homo sapiens	135-139
35007085-7	2022	The optimal polymer displays potent activity against antibiotic-resistant bacteria and high therapeutic efficacy in treating MRSA-induced wound infections and keratitis as well as low acute dermal toxicity and low corneal epithelial cytotoxicity.	Polymers	12-19	solute carrier family 9 member A6	Homo sapiens	125-129
3266621-1	1988	Methicillin and gentamicin resistant strains of Staphylococcus aureus (MRSA) remains a cause of significant morbidity and mortality.	Gentamicins	16-26	solute carrier family 9 member A6	Homo sapiens	71-75
3266621-7	1988	We believe that our data support the use of trimethoprim-sulphamethoxazole as a potentially economical and effective alternative for the treatment of infections caused by MRSA.	Trimethoprim, Sulfamethoxazole Drug Combination	44-74	solute carrier family 9 member A6	Homo sapiens	171-175
33663553-2	2021	We recently found that NHE6 directly interacts with secretory carrier membrane protein 5 (SCAMP5), and SCAMP5-dependent recruitment of NHE6 to SVs controls the strength of synaptic transmission by modulation of quantal size of glutamate release at rest.	Glutamic Acid	227-236	solute carrier family 9 member A6	Homo sapiens	23-27
2871075-1	1986	An outbreak of gentamicin-methicillin-resistant Staphylococcus aureus (gentamicin-resistant MRSA) which occurred during 1983-84 at the Whittington Hospital, London, is described.	Gentamicins	15-25	solute carrier family 9 member A6	Homo sapiens	92-96
2871075-1	1986	An outbreak of gentamicin-methicillin-resistant Staphylococcus aureus (gentamicin-resistant MRSA) which occurred during 1983-84 at the Whittington Hospital, London, is described.	Gentamicins	71-81	solute carrier family 9 member A6	Homo sapiens	92-96
2871075-4	1986	Six members of staff and one patient were colonized with gentamicin-resistant MRSA.	Gentamicins	57-67	solute carrier family 9 member A6	Homo sapiens	78-82
2871075-6	1986	Seventeen patients and staff were treated with this agent and all were cleared of the original gentamicin-resistant MRSA.	Gentamicins	95-105	solute carrier family 9 member A6	Homo sapiens	116-120
2871075-8	1986	Sporadic cases of gentamicin-resistant MRSA still occur at infrequent intervals.	Gentamicins	18-28	solute carrier family 9 member A6	Homo sapiens	39-43
33754480-0	2021	Designing a leucine-rich antibacterial nonapeptide with potent activity against mupirocin-resistant MRSA via a structure-activity relationship study.	Leucine	12-19	solute carrier family 9 member A6	Homo sapiens	100-104
33754480-0	2021	Designing a leucine-rich antibacterial nonapeptide with potent activity against mupirocin-resistant MRSA via a structure-activity relationship study.	Mupirocin	80-89	solute carrier family 9 member A6	Homo sapiens	100-104
33754480-2	2021	Of particular concern is the methicillin-resistant variety, commonly known as MRSA.	Methicillin	29-40	solute carrier family 9 member A6	Homo sapiens	78-82
33754480-4	2021	In this work, we describe how we designed a novel cationic nonapeptide, containing only leucine and two lysine residues, with potent anti-MRSA activity and a rapid bactericidal mode of action.	Leucine	88-95	solute carrier family 9 member A6	Homo sapiens	138-142
33754480-4	2021	In this work, we describe how we designed a novel cationic nonapeptide, containing only leucine and two lysine residues, with potent anti-MRSA activity and a rapid bactericidal mode of action.	Lysine	104-110	solute carrier family 9 member A6	Homo sapiens	138-142
34025612-1	2021	Methicillin-resistant Staphylococcus aureus (MRSA) belonging to clonal complex 361 (CC361-MRSA) is rare among patients" populations globally.	Methicillin	0-11	solute carrier family 9 member A6	Homo sapiens	45-49
33663553-2	2021	We recently found that NHE6 directly interacts with secretory carrier membrane protein 5 (SCAMP5), and SCAMP5-dependent recruitment of NHE6 to SVs controls the strength of synaptic transmission by modulation of quantal size of glutamate release at rest.	Glutamic Acid	227-236	solute carrier family 9 member A6	Homo sapiens	135-139
33663553-4	2021	Here, we found that the number of NHE6-positive presynaptic boutons was significantly increased by the chemical long-term potentiation (cLTP).	cltp	136-140	solute carrier family 9 member A6	Homo sapiens	34-38
33663553-5	2021	Since cLTP involves new synapse formation, our results indicated that NHE6 was recruited not only to the existing presynaptic boutons but also to the newly formed presynaptic boutons.	cltp	6-10	solute carrier family 9 member A6	Homo sapiens	70-74
33663553-6	2021	Knock down of SCAMP5 completely abrogated the enhancement of NHE6 recruitment by cLTP.	cltp	81-85	solute carrier family 9 member A6	Homo sapiens	61-65
33663553-7	2021	Interestingly, despite an increase in the number of NHE6-positive boutons by cLTP, the quantal size of glutamate release at the presynaptic terminals remained unaltered.	cltp	77-81	solute carrier family 9 member A6	Homo sapiens	52-56
33608606-0	2021	Association between fluoroquinolone resistance and MRSA genotype in Alexandria, Egypt.	Fluoroquinolones	20-35	solute carrier family 9 member A6	Homo sapiens	51-55
33551346-6	2021	The aspirated fluid was sent for culture and sensitivity that revealed MRSA sensitive to vancomycin and linezolid.	Vancomycin	89-99	solute carrier family 9 member A6	Homo sapiens	71-75
33551346-6	2021	The aspirated fluid was sent for culture and sensitivity that revealed MRSA sensitive to vancomycin and linezolid.	Linezolid	104-113	solute carrier family 9 member A6	Homo sapiens	71-75
33496582-3	2021	The anti-bacterial and cell cytotoxic activity of the compounds were compared to the potent anti-MRSA compound rubrolide A; hydration across the C-5/C-6 bond was shown to abrogate antibacterial activity.	rubrolide A	111-122	solute carrier family 9 member A6	Homo sapiens	97-101
33608606-12	2021	We recommend caution in treating MRSA infections with moxifloxacin.	Moxifloxacin	54-66	solute carrier family 9 member A6	Homo sapiens	33-37
33372133-5	2021	The use of optical imaging and electrophysiological recording showed that small hairpin RNA-mediated knockdown (KD) of SCAMP5 or perturbation of SCAMP5/NHE6 interaction markedly inhibited axonal trafficking and the presynaptic localization of NHE6, leading to hyperacidification of SVs and a reduction in the quantal size of glutamate release.	Glutamic Acid	325-334	solute carrier family 9 member A6	Homo sapiens	152-156
33057715-0	2021	Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage.	tedizolid	26-35	solute carrier family 9 member A6	Homo sapiens	67-71
33057715-1	2021	OBJECTIVES: Tedizolid is an oxazolidinone antimicrobial with activity against Gram-positive bacteria, including MRSA.	tedizolid	12-21	solute carrier family 9 member A6	Homo sapiens	112-116
33057715-1	2021	OBJECTIVES: Tedizolid is an oxazolidinone antimicrobial with activity against Gram-positive bacteria, including MRSA.	Oxazolidinones	28-41	solute carrier family 9 member A6	Homo sapiens	112-116
33057715-3	2021	The objective of this study was to further explore the phenotypic and genetic basis of tedizolid resistance in MRSA.	tedizolid	87-96	solute carrier family 9 member A6	Homo sapiens	111-115
33057715-4	2021	METHODS: We selected for tedizolid resistance in an MRSA laboratory strain, N315, by serial passage until an isolate with an MIC >=1 log2 dilution above the breakpoint for resistance (>=2 mg/L) was recovered.	tedizolid	25-34	solute carrier family 9 member A6	Homo sapiens	52-56
33057715-4	2021	METHODS: We selected for tedizolid resistance in an MRSA laboratory strain, N315, by serial passage until an isolate with an MIC >=1 log2 dilution above the breakpoint for resistance (>=2 mg/L) was recovered.	2-Fluoro-6-methylnicotinonitrile	76-80	solute carrier family 9 member A6	Homo sapiens	52-56
31993042-0	2019	Linezolid and Rifampicin Combination to Combat cfr-Positive Multidrug-Resistant MRSA in Murine Models of Bacteremia and Skin and Skin Structure Infection.	linezolid	0-9	solute carrier family 9 member A6	Homo sapiens	80-84
32891858-0	2020	Design and synthesis of novel desfluoroquinolone-aminopyrimidine hybrids as potent anti-MRSA agents with low hERG activity.	desfluoroquinolone	30-48	solute carrier family 9 member A6	Homo sapiens	88-92
32891858-0	2020	Design and synthesis of novel desfluoroquinolone-aminopyrimidine hybrids as potent anti-MRSA agents with low hERG activity.	2-aminopyrimidine	49-64	solute carrier family 9 member A6	Homo sapiens	88-92
32449440-7	2020	Tedizolid exhibits antibacterial activity against the most important ABSSSI pathogens (including multidrug resistant strains of MRSA), as well as mycobacteria and Nocardia.	tedizolid	0-9	solute carrier family 9 member A6	Homo sapiens	128-132
32016379-0	2020	Occurrence of cross-resistance and beta-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels.	beta-Lactams	35-46	solute carrier family 9 member A6	Homo sapiens	123-127
32016379-0	2020	Occurrence of cross-resistance and beta-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels.	Phosphatidylglycerols	153-173	solute carrier family 9 member A6	Homo sapiens	123-127
32016379-2	2020	Cross-resistance among these antibiotics in MRSA is well documented, as is the observation that susceptibility of MRSA to beta-lactams increases as susceptibility to GPs and LPs decreases (i.e. the seesaw effect).	beta-Lactams	122-134	solute carrier family 9 member A6	Homo sapiens	44-48
32016379-2	2020	Cross-resistance among these antibiotics in MRSA is well documented, as is the observation that susceptibility of MRSA to beta-lactams increases as susceptibility to GPs and LPs decreases (i.e. the seesaw effect).	beta-Lactams	122-134	solute carrier family 9 member A6	Homo sapiens	114-118
31859331-0	2020	Platinum ions mediate the interactions between DNA and carbon quantum dots: diagnosis of MRSA infections.	Platinum	0-8	solute carrier family 9 member A6	Homo sapiens	89-93
31859331-0	2020	Platinum ions mediate the interactions between DNA and carbon quantum dots: diagnosis of MRSA infections.	Carbon	55-61	solute carrier family 9 member A6	Homo sapiens	89-93
31859331-1	2020	In this study, we have developed a rapid and cost-effective method employing platinum ion (Pt4+)-capped fluorescent carbon quantum dots (CQDs) coupled with loop-mediated isothermal amplification (LAMP) to detect dual MRSA genes.	Platinum	77-85	solute carrier family 9 member A6	Homo sapiens	217-221
31859331-1	2020	In this study, we have developed a rapid and cost-effective method employing platinum ion (Pt4+)-capped fluorescent carbon quantum dots (CQDs) coupled with loop-mediated isothermal amplification (LAMP) to detect dual MRSA genes.	Platinum	91-95	solute carrier family 9 member A6	Homo sapiens	217-221
31859331-1	2020	In this study, we have developed a rapid and cost-effective method employing platinum ion (Pt4+)-capped fluorescent carbon quantum dots (CQDs) coupled with loop-mediated isothermal amplification (LAMP) to detect dual MRSA genes.	Carbon	116-122	solute carrier family 9 member A6	Homo sapiens	217-221
31859331-3	2020	The CQDSPDs capped with Pt4+ ions through the cooperative coordination of the amine and chlorine groups on the surface of CQDs facilitated the double-stranded DNA (dsDNA)-induced fluorescence quenching of CQDs, and enabled the construction of the CQDSPDs/Pt4+ probe for the detection of as few as 10 copies of the MRSA gene (mecA and femA).	Platinum	24-28	solute carrier family 9 member A6	Homo sapiens	314-318
31859331-3	2020	The CQDSPDs capped with Pt4+ ions through the cooperative coordination of the amine and chlorine groups on the surface of CQDs facilitated the double-stranded DNA (dsDNA)-induced fluorescence quenching of CQDs, and enabled the construction of the CQDSPDs/Pt4+ probe for the detection of as few as 10 copies of the MRSA gene (mecA and femA).	Amines	78-83	solute carrier family 9 member A6	Homo sapiens	314-318
31859331-3	2020	The CQDSPDs capped with Pt4+ ions through the cooperative coordination of the amine and chlorine groups on the surface of CQDs facilitated the double-stranded DNA (dsDNA)-induced fluorescence quenching of CQDs, and enabled the construction of the CQDSPDs/Pt4+ probe for the detection of as few as 10 copies of the MRSA gene (mecA and femA).	Chlorine	88-96	solute carrier family 9 member A6	Homo sapiens	314-318
31859331-3	2020	The CQDSPDs capped with Pt4+ ions through the cooperative coordination of the amine and chlorine groups on the surface of CQDs facilitated the double-stranded DNA (dsDNA)-induced fluorescence quenching of CQDs, and enabled the construction of the CQDSPDs/Pt4+ probe for the detection of as few as 10 copies of the MRSA gene (mecA and femA).	Platinum	255-259	solute carrier family 9 member A6	Homo sapiens	314-318
31859331-4	2020	The sensitivity and specificity of the CQDSPDs/Pt4+ probe for MRSA detection in clinical specimens (n = 24) were 94% and 86%, respectively.	Platinum	47-51	solute carrier family 9 member A6	Homo sapiens	62-66
32123664-8	2020	The patient was treated with two weeks of IV ceftriaxone and was discharged with plans to complete a six-week course of IV daptomycin due to MRSA bacteremia.	Daptomycin	123-133	solute carrier family 9 member A6	Homo sapiens	141-145
33325700-0	2020	Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.	Adenine	22-29	solute carrier family 9 member A6	Homo sapiens	116-120
33325700-0	2020	Discovery of a Potent Adenine-Benzyltriazolo-Pleuromutilin Conjugate with Pronounced Antibacterial Activity against MRSA.	benzyltriazolo-pleuromutilin	30-58	solute carrier family 9 member A6	Homo sapiens	116-120
33026882-5	2020	Through systematic analysis, we found that herbal extracts combined with antibiotics, such as beta-lactams, quinolones, aminoglycosides, tetracyclines and glycopeptides, could greatly enhance the antibacterial effects of the antibiotics, reduce the dosage and toxic side effects, and reverse MRSA resistance.	beta-Lactams	94-106	solute carrier family 9 member A6	Homo sapiens	292-296
33026882-5	2020	Through systematic analysis, we found that herbal extracts combined with antibiotics, such as beta-lactams, quinolones, aminoglycosides, tetracyclines and glycopeptides, could greatly enhance the antibacterial effects of the antibiotics, reduce the dosage and toxic side effects, and reverse MRSA resistance.	Quinolones	108-118	solute carrier family 9 member A6	Homo sapiens	292-296
33026882-5	2020	Through systematic analysis, we found that herbal extracts combined with antibiotics, such as beta-lactams, quinolones, aminoglycosides, tetracyclines and glycopeptides, could greatly enhance the antibacterial effects of the antibiotics, reduce the dosage and toxic side effects, and reverse MRSA resistance.	Aminoglycosides	120-135	solute carrier family 9 member A6	Homo sapiens	292-296
33026882-5	2020	Through systematic analysis, we found that herbal extracts combined with antibiotics, such as beta-lactams, quinolones, aminoglycosides, tetracyclines and glycopeptides, could greatly enhance the antibacterial effects of the antibiotics, reduce the dosage and toxic side effects, and reverse MRSA resistance.	Tetracyclines	137-150	solute carrier family 9 member A6	Homo sapiens	292-296
33026882-5	2020	Through systematic analysis, we found that herbal extracts combined with antibiotics, such as beta-lactams, quinolones, aminoglycosides, tetracyclines and glycopeptides, could greatly enhance the antibacterial effects of the antibiotics, reduce the dosage and toxic side effects, and reverse MRSA resistance.	Glycopeptides	155-168	solute carrier family 9 member A6	Homo sapiens	292-296
32542310-11	2020	Delafloxacin was active against 94% of MRSA blood isolates that were genotype SCC IVa.	delafloxacin	0-12	solute carrier family 9 member A6	Homo sapiens	39-43
32542310-13	2020	CONCLUSIONS: Delafloxacin demonstrates superior activity to levofloxacin against recent MRSA blood isolates, VISA, VRSA and DNSSA, and demonstrates good activity against blood isolates most commonly found in the community.	delafloxacin	13-25	solute carrier family 9 member A6	Homo sapiens	88-92
32279050-0	2020	Synthesis of novel monocarbonyl curcuminoids, evaluation of their efficacy against MRSA, including ex vivo infection model and their mechanistic studies.	Diarylheptanoids	32-44	solute carrier family 9 member A6	Homo sapiens	83-87
32279050-7	2020	Therefore, the present study affords us water-soluble, stable, non-toxic curcuminoids that may serve as lead molecules for development as antibacterial agents against MRSA infections.	Water	40-45	solute carrier family 9 member A6	Homo sapiens	167-171
32279050-7	2020	Therefore, the present study affords us water-soluble, stable, non-toxic curcuminoids that may serve as lead molecules for development as antibacterial agents against MRSA infections.	Diarylheptanoids	73-85	solute carrier family 9 member A6	Homo sapiens	167-171
32392437-3	2020	Objective: To assess colonization rates and changes in colonization patterns of methicillin-resistant or methicillin-sensitive Staphylococcus aureus (MRSA/MSSA) in nasal flora in patients undergoing nasal surgery and to determine whether colonization is a risk factor for postoperative infection.	Methicillin	80-91	solute carrier family 9 member A6	Homo sapiens	150-154
32392437-3	2020	Objective: To assess colonization rates and changes in colonization patterns of methicillin-resistant or methicillin-sensitive Staphylococcus aureus (MRSA/MSSA) in nasal flora in patients undergoing nasal surgery and to determine whether colonization is a risk factor for postoperative infection.	Methicillin	105-116	solute carrier family 9 member A6	Homo sapiens	150-154
31993042-0	2019	Linezolid and Rifampicin Combination to Combat cfr-Positive Multidrug-Resistant MRSA in Murine Models of Bacteremia and Skin and Skin Structure Infection.	Rifampin	14-24	solute carrier family 9 member A6	Homo sapiens	80-84
31993042-1	2019	Linezolid resistance mediated by the cfr gene in MRSA represents a global concern.	linezolid	0-9	solute carrier family 9 member A6	Homo sapiens	49-53
31993042-5	2019	In vitro phenotypes of cfr-positive MRSA translated into poor outcomes of linezolid monotherapy in vivo in murine bacteremia and SSSI models.	linezolid	74-83	solute carrier family 9 member A6	Homo sapiens	36-40
31993042-8	2019	Altogether, these data suggest that the use of linezolid in combination with rifampicin poses a viable therapeutic alternative for bacteremia and SSSI caused by cfr-positive multidrug resistant MRSA.	linezolid	47-56	solute carrier family 9 member A6	Homo sapiens	194-198
31993042-8	2019	Altogether, these data suggest that the use of linezolid in combination with rifampicin poses a viable therapeutic alternative for bacteremia and SSSI caused by cfr-positive multidrug resistant MRSA.	Rifampin	77-87	solute carrier family 9 member A6	Homo sapiens	194-198
32047717-1	2019	Background: Isolation precautions used in methicillin-resistant Staph ylo coc cus aureus (MRSA) infection control are effective in inhibiting pathogen transmission, but may cause unintended consequences in medical care.	Methicillin	42-53	solute carrier family 9 member A6	Homo sapiens	90-94
31523763-1	2020	Traditional antimicrobial susceptibility test methods for detection of S. aureus resistant to oxacillin (MRSA) such as disk diffusion, broth microdilution, and oxacillin screen plate require 18-24 h of incubation after having the organism growing in pure culture.	Oxacillin	94-103	solute carrier family 9 member A6	Homo sapiens	105-109
31523763-1	2020	Traditional antimicrobial susceptibility test methods for detection of S. aureus resistant to oxacillin (MRSA) such as disk diffusion, broth microdilution, and oxacillin screen plate require 18-24 h of incubation after having the organism growing in pure culture.	Oxacillin	160-169	solute carrier family 9 member A6	Homo sapiens	105-109
31676550-0	2019	Functional Assessment In Vivo of the Mouse Homolog of the Human Ala-9-Ser NHE6 Variant.	ala-9-ser	64-73	solute carrier family 9 member A6	Homo sapiens	74-78
31377954-1	2019	To review the epidemiology and measures to control meticillin-resistant Staphylococcus aureus, MRSA, in Stockholm between 2000 and 2016 from the perspective of the Department of Communicable Disease Control and Prevention, Stockholm County Council, Sweden.	Methicillin	51-61	solute carrier family 9 member A6	Homo sapiens	95-99
30753447-1	2019	Background: Information on outcomes of methicillin-susceptible and -resistant S. aureus (MSSA and MRSA, respectively) bacteremia, particularly readmission is scarce, and require further research to inform optimal patient care.	Methicillin	39-50	solute carrier family 9 member A6	Homo sapiens	98-102
31728264-0	2019	Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data.	dalbavancin	50-61	solute carrier family 9 member A6	Homo sapiens	75-79
31505641-9	2019	MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%).	ceftobiprole	30-42	solute carrier family 9 member A6	Homo sapiens	0-4
31175985-0	2019	A Christianson syndrome-linked deletion mutation (Delta287ES288) in SLC9A6 impairs hippocampal neuronal plasticity.	delta287es288	50-63	solute carrier family 9 member A6	Homo sapiens	68-74
31505641-9	2019	MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%).	Linezolid	44-53	solute carrier family 9 member A6	Homo sapiens	0-4
31505641-9	2019	MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%).	telavancin	58-68	solute carrier family 9 member A6	Homo sapiens	0-4
31505641-9	2019	MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%).	Daptomycin	77-87	solute carrier family 9 member A6	Homo sapiens	0-4
31505641-9	2019	MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%).	Vancomycin	97-107	solute carrier family 9 member A6	Homo sapiens	0-4
31505641-9	2019	MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%).	Tigecycline	120-131	solute carrier family 9 member A6	Homo sapiens	0-4
30994105-1	2019	IntroductionMeticillin-resistant Staphylococcus aureus (MRSA) is a major cause of healthcare-associated infections.AimWe describe MRSA colonisation/infection and bacteraemia rate trends in Dutch-German border region hospitals (NL-DE-BRH) in 2012-16.MethodsAll 42 NL-DE BRH (8 NL-BRH, 34 DE-BRH) within the cross-border network EurSafety Health-net provided surveillance data (on average ca 620,000 annual hospital admissions, of these 68.0% in Germany).	introductionmeticillin	0-22	solute carrier family 9 member A6	Homo sapiens	56-60
30726929-0	2019	Genomic characterization of inpatient evolution of MRSA resistant to daptomycin, vancomycin and ceftaroline.	Daptomycin	69-79	solute carrier family 9 member A6	Homo sapiens	51-55
30726929-0	2019	Genomic characterization of inpatient evolution of MRSA resistant to daptomycin, vancomycin and ceftaroline.	Vancomycin	81-91	solute carrier family 9 member A6	Homo sapiens	51-55
30726929-0	2019	Genomic characterization of inpatient evolution of MRSA resistant to daptomycin, vancomycin and ceftaroline.	T 91825	96-107	solute carrier family 9 member A6	Homo sapiens	51-55
30825723-0	2019	Synthesis and biological evaluation of 7-substituted cycloberberine derivatives as potent antibacterial agents against MRSA.	7-substituted cycloberberine	39-67	solute carrier family 9 member A6	Homo sapiens	119-123
30994105-1	2019	IntroductionMeticillin-resistant Staphylococcus aureus (MRSA) is a major cause of healthcare-associated infections.AimWe describe MRSA colonisation/infection and bacteraemia rate trends in Dutch-German border region hospitals (NL-DE-BRH) in 2012-16.MethodsAll 42 NL-DE BRH (8 NL-BRH, 34 DE-BRH) within the cross-border network EurSafety Health-net provided surveillance data (on average ca 620,000 annual hospital admissions, of these 68.0% in Germany).	introductionmeticillin	0-22	solute carrier family 9 member A6	Homo sapiens	130-134
29890954-1	2018	BACKGROUND: Consideration to add empiric MRSA therapy with vancomycin is a common clinical dilemma.	Vancomycin	59-69	solute carrier family 9 member A6	Homo sapiens	41-45
30103288-0	2019	Designing an ultra-short antibacterial peptide with potent activity against Mupirocin-resistant MRSA.	Mupirocin	76-85	solute carrier family 9 member A6	Homo sapiens	96-100
30103288-2	2019	In particular, the methicillin-resistant variety, MRSA, has become a global clinical concern.	Methicillin	19-30	solute carrier family 9 member A6	Homo sapiens	50-54
30103288-3	2019	The extensive use of mupirocin, the first-line topical antibacterial drug of choice, has led to the emergence of mupirocin-resistant MRSA globally, resulting in the urgent need for a replacement.	Mupirocin	21-30	solute carrier family 9 member A6	Homo sapiens	133-137
30103288-3	2019	The extensive use of mupirocin, the first-line topical antibacterial drug of choice, has led to the emergence of mupirocin-resistant MRSA globally, resulting in the urgent need for a replacement.	Mupirocin	113-122	solute carrier family 9 member A6	Homo sapiens	133-137
30316060-1	2018	The design, synthesis and evaluation of a small series of potent amphiphilic norbornane antibacterial agents has been performed (compound 10 MIC = 0.25 mug/mL against MRSA).	Norbornanes	77-87	solute carrier family 9 member A6	Homo sapiens	167-171
30316060-3	2018	Two fluorescent analogues (compound 29 with 4-amino-naphthalimide and 34 with 4-nitrobenz-2-oxa-1,3-diazole fluorophores) with good activity (MIC = 0.5 mug/mL against MRSA) were also constructed and confocal microscopy studies indicate that the primary site of interaction for this family of compounds is the bacterial membrane.	4-nitrobenz-2-oxa-1,3-diazole fluorophores	78-120	solute carrier family 9 member A6	Homo sapiens	167-171
31192222-10	2019	In postmortem brains from the ROS/MAP dataset of normal and pathological aging, decreased NHE6 expression was correlated with greater tau deposition.	ros	30-33	solute carrier family 9 member A6	Homo sapiens	90-94
30535122-11	2019	Standard linezolid dosing in obese pneumonia patients with MRSA (MICs of 1-4 mg/L) leads to unacceptably low (near zero to 60%) PTA for patients <65 years old.	Linezolid	9-18	solute carrier family 9 member A6	Homo sapiens	59-63
30535122-13	2019	Body weight and especially age are important characteristics to be considered when administering linezolid to treat MRSA infections.	Linezolid	97-106	solute carrier family 9 member A6	Homo sapiens	116-120
30230671-0	2018	Transcript Profiling of MRSA Biofilms Treated with a Halogenated Phenazine Eradicating Agent: A Platform for Defining Cellular Targets and Pathways Critical to Biofilm Survival.	phenazine	65-74	solute carrier family 9 member A6	Homo sapiens	24-28
30230671-4	2018	WoPPER analysis with time-course validation (RT-qPCR) revealed that HP-14 induces rapid iron starvation in MRSA biofilms, as evident by the activation of iron-acquisition gene clusters in 1 hour.	Iron	88-92	solute carrier family 9 member A6	Homo sapiens	107-111
30230671-4	2018	WoPPER analysis with time-course validation (RT-qPCR) revealed that HP-14 induces rapid iron starvation in MRSA biofilms, as evident by the activation of iron-acquisition gene clusters in 1 hour.	Iron	154-158	solute carrier family 9 member A6	Homo sapiens	107-111
30230671-7	2018	These findings suggest that MRSA biofilm viability relies on iron homeostasis.	Iron	61-65	solute carrier family 9 member A6	Homo sapiens	28-32
29755606-7	2018	We detected a high resistance rate to common antibiotics, e.g. 83% of S. aureus isolates were resistant to oxacillin (MRSA).	Oxacillin	107-116	solute carrier family 9 member A6	Homo sapiens	118-122
29777150-0	2018	Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility.	Vancomycin	108-118	solute carrier family 9 member A6	Homo sapiens	90-94
29777150-1	2018	Bacteremia caused by MRSA with reduced vancomycin susceptibility (MRSA-RVS) frequently resulted in treatment failure and mortality.	Vancomycin	39-49	solute carrier family 9 member A6	Homo sapiens	21-25
29777150-1	2018	Bacteremia caused by MRSA with reduced vancomycin susceptibility (MRSA-RVS) frequently resulted in treatment failure and mortality.	Vancomycin	39-49	solute carrier family 9 member A6	Homo sapiens	66-70
29777150-3	2018	We retrospectively reviewed clinical data of patients with bacteremia caused by MRSA with vancomycin MIC = 2 mg/L from 2009 to 2012.	Vancomycin	90-100	solute carrier family 9 member A6	Homo sapiens	80-84
29244141-4	2018	Patients and methods: This was a retrospective study of hospitalized patients at two tertiary care academic medical centres with recurrent or persistent (>=3 days) MRSA-B treated with telavancin monotherapy.	telavancin	187-197	solute carrier family 9 member A6	Homo sapiens	167-171
30250892-2	2018	We recently identified a conceptually novel mechanism for how dysregulated pH in hypoxic cells causes chemoresistance which is based on the aberrant cellular distribution of the endosomal pH regulator, the sodium/hydrogen exchanger 6 (NHE6).	Sodium	206-212	solute carrier family 9 member A6	Homo sapiens	235-239
30250892-2	2018	We recently identified a conceptually novel mechanism for how dysregulated pH in hypoxic cells causes chemoresistance which is based on the aberrant cellular distribution of the endosomal pH regulator, the sodium/hydrogen exchanger 6 (NHE6).	Hydrogen	213-221	solute carrier family 9 member A6	Homo sapiens	235-239
29244141-6	2018	Results: Telavancin dosed 10 mg/kg three times weekly post-IHD or 10 mg/kg every 48 h resulted in microbiological cure in 7/8 (87.5%) refractory MRSA-B cases.	telavancin	9-19	solute carrier family 9 member A6	Homo sapiens	145-149
29244141-9	2018	Conclusions: Telavancin was very safe and highly effective in the treatment of refractory MRSA-B in a cohort of patients with ESRD requiring IHD.	telavancin	13-23	solute carrier family 9 member A6	Homo sapiens	90-94
28962026-0	2017	Pharmacodynamics of teicoplanin against MRSA.	Teicoplanin	20-31	solute carrier family 9 member A6	Homo sapiens	40-44
29258622-6	2017	MRSA was detected using both Cefoxitin (30 mug) and Oxacillin (6 mug) (Oxoid Ltd. England) discs in combination and associated factors were assessed using self-administered pretested questionnaires, which were delivered to the children"s parents/guardians.	Cefoxitin	29-38	solute carrier family 9 member A6	Homo sapiens	0-4
29258622-6	2017	MRSA was detected using both Cefoxitin (30 mug) and Oxacillin (6 mug) (Oxoid Ltd. England) discs in combination and associated factors were assessed using self-administered pretested questionnaires, which were delivered to the children"s parents/guardians.	Oxacillin	52-61	solute carrier family 9 member A6	Homo sapiens	0-4
28962026-1	2017	Objectives: The overall study aim was to identify the relevant preclinical teicoplanin pharmacokinetic (PK)/pharmacodynamic (PD) indices to predict efficacy and suppression of resistance in MRSA infection.	Teicoplanin	75-86	solute carrier family 9 member A6	Homo sapiens	190-194
28962026-10	2017	Conclusions: This study improves our understanding of teicoplanin PD against MRSA and defines an in vivo AUC/MIC target for efficacy and suppression of resistance.	Teicoplanin	54-65	solute carrier family 9 member A6	Homo sapiens	77-81
29029278-1	2017	Background: Delafloxacin is an investigational anionic fluoroquinolone in development for oral or intravenous administration for the treatment of infections caused by Gram-positive (including MRSA), Gram-negative, atypical and anaerobic organisms.	delafloxacin	12-24	solute carrier family 9 member A6	Homo sapiens	192-196
28552898-5	2017	Results indicated that the vancomycin-coated sample was biocompatible for Human osteoblast cell line MG-63 and displayed effective antibacterial ability against MRSA.	Vancomycin	27-37	solute carrier family 9 member A6	Homo sapiens	161-165
29029278-9	2017	Bacterial eradication of MRSA was 100% and 98.5% in the delafloxacin group and the vancomycin/aztreonam group, respectively.	delafloxacin	56-68	solute carrier family 9 member A6	Homo sapiens	25-29
29029278-9	2017	Bacterial eradication of MRSA was 100% and 98.5% in the delafloxacin group and the vancomycin/aztreonam group, respectively.	Vancomycin	83-93	solute carrier family 9 member A6	Homo sapiens	25-29
29029278-9	2017	Bacterial eradication of MRSA was 100% and 98.5% in the delafloxacin group and the vancomycin/aztreonam group, respectively.	Aztreonam	94-103	solute carrier family 9 member A6	Homo sapiens	25-29
28265870-6	2017	The increased consumption of amoxicillin/clavulanate and piperacillin/tazobactam was associated with the reduction of MRSA rate from 48.5 to 25.9% (p = 0.007 and p = 0.04, respectively).	Amoxicillin-Potassium Clavulanate Combination	29-52	solute carrier family 9 member A6	Homo sapiens	118-122
28265870-6	2017	The increased consumption of amoxicillin/clavulanate and piperacillin/tazobactam was associated with the reduction of MRSA rate from 48.5 to 25.9% (p = 0.007 and p = 0.04, respectively).	Piperacillin, Tazobactam Drug Combination	57-80	solute carrier family 9 member A6	Homo sapiens	118-122
27774857-0	2017	In-vitro activity of ceftriaxone combined with newer agents against MRSA.	Ceftriaxone	21-32	solute carrier family 9 member A6	Homo sapiens	68-72
27774857-1	2017	In this study, in vitro synergism in combinations of agents as ceftriaxone/dalbavancin, ceftriaxone/linezolid and ceftriaxone/daptomycin against MRSA strains were investigated.	Linezolid	100-109	solute carrier family 9 member A6	Homo sapiens	145-149
28676409-4	2017	The recommended perioperative prophylaxis was cefuroxime (or vancomycin in case of documented MRSA body carriage).	Vancomycin	61-71	solute carrier family 9 member A6	Homo sapiens	94-98
28824185-6	2017	Patients with MRSA infection were additionally administered intravenous vancomycin in combination with either oral rifampicin or trimethoprim-sulfamethoxazole.	Vancomycin	72-82	solute carrier family 9 member A6	Homo sapiens	14-18
28578731-0	2017	Bacterial Infections in Neonates Following Mupirocin-Based MRSA Decolonization: A Multicenter Cohort Study.	Mupirocin	43-52	solute carrier family 9 member A6	Homo sapiens	59-63
28578731-1	2017	OBJECTIVE To characterize the risk of infection after MRSA decolonization with intranasal mupirocin.	Mupirocin	90-99	solute carrier family 9 member A6	Homo sapiens	54-58
28578731-8	2017	Of the MRSA-colonized neonates, 384 (74%) received mupirocin.	Mupirocin	51-60	solute carrier family 9 member A6	Homo sapiens	7-11
28578731-11	2017	CONCLUSIONS In this multicentered cohort of MRSA-colonized neonates, mupirocin-based decolonization treatment appeared to decrease the risk of infection with select gram-positive organisms as intended, and the treatment was not significantly associated with risk of subsequent infections with organisms not covered by mupirocin"s spectrum of activity.	Mupirocin	69-78	solute carrier family 9 member A6	Homo sapiens	44-48
27999030-7	2017	MRSA and MSSA carriers were less likely than SA non-carriers to be female (50% and 56% versus 68%, P  = 0.03) or to have recently used beta-lactam antibiotics (43% and 65% versus 73%, P  = 0.01).	beta-Lactams	135-146	solute carrier family 9 member A6	Homo sapiens	0-4
28473167-13	2017	Glycopeptide (e.g.Teicoplanin) prophylaxis should be considered when there is history of MRSA colonization or MRSA screening results are not available before the surgery.	Teicoplanin	18-29	solute carrier family 9 member A6	Homo sapiens	89-93
28473167-13	2017	Glycopeptide (e.g.Teicoplanin) prophylaxis should be considered when there is history of MRSA colonization or MRSA screening results are not available before the surgery.	Teicoplanin	18-29	solute carrier family 9 member A6	Homo sapiens	110-114
28343752-7	2017	In mixed infection model, tedizolid therapy showed similar antimicrobial activities for one MRSA and two P. anaerobius isolates evaluated, compared with linezolid therapy.	tedizolid	26-35	solute carrier family 9 member A6	Homo sapiens	92-96
28343752-9	2017	CONCLUSION: In the neutropenic murine thigh infection model, human simulated exposures of tedizolid and linezolid resulted in similar efficacies against MRSA, even though single and mixed infection models were used.	tedizolid	90-99	solute carrier family 9 member A6	Homo sapiens	153-157
28343752-9	2017	CONCLUSION: In the neutropenic murine thigh infection model, human simulated exposures of tedizolid and linezolid resulted in similar efficacies against MRSA, even though single and mixed infection models were used.	Linezolid	104-113	solute carrier family 9 member A6	Homo sapiens	153-157
28473167-11	2017	Of those receiving cefuroxime, five (22.73%) patients developed postoperative MRSA surgical site infection (SSI) but none of those (0%) receiving Teicoplanin had MRSA SSI.	Cefuroxime	19-29	solute carrier family 9 member A6	Homo sapiens	78-82
28343752-5	2017	RESULTS: The tedizolid and linezolid MICs for MRSA was 0.25 and 2 mug/ml.	tedizolid	13-22	solute carrier family 9 member A6	Homo sapiens	46-50
28343752-5	2017	RESULTS: The tedizolid and linezolid MICs for MRSA was 0.25 and 2 mug/ml.	Linezolid	27-36	solute carrier family 9 member A6	Homo sapiens	46-50
28314920-5	2017	In part, only expert opinions are given due to lack of study results.The two 5th generation cephalosporins ceftaroline and ceftobiprole have beside their equivalent efficacy to ceftriaxone (ceftaroline) and cefipim (ceftobiprole) high activity against MRSA.	Cephalosporins	92-106	solute carrier family 9 member A6	Homo sapiens	252-256
28314920-5	2017	In part, only expert opinions are given due to lack of study results.The two 5th generation cephalosporins ceftaroline and ceftobiprole have beside their equivalent efficacy to ceftriaxone (ceftaroline) and cefipim (ceftobiprole) high activity against MRSA.	T 91825	107-118	solute carrier family 9 member A6	Homo sapiens	252-256
28314920-5	2017	In part, only expert opinions are given due to lack of study results.The two 5th generation cephalosporins ceftaroline and ceftobiprole have beside their equivalent efficacy to ceftriaxone (ceftaroline) and cefipim (ceftobiprole) high activity against MRSA.	ceftobiprole	123-135	solute carrier family 9 member A6	Homo sapiens	252-256
28314920-7	2017	The oxazolidinone tedizolid is effective against linezolid-resistant MRSA.	Oxazolidinones	4-17	solute carrier family 9 member A6	Homo sapiens	69-73
28314920-7	2017	The oxazolidinone tedizolid is effective against linezolid-resistant MRSA.	tedizolid	18-27	solute carrier family 9 member A6	Homo sapiens	69-73
28314920-7	2017	The oxazolidinone tedizolid is effective against linezolid-resistant MRSA.	Linezolid	49-58	solute carrier family 9 member A6	Homo sapiens	69-73
28900682-7	2017	While infections caused by methicillin-susceptible S. aureus (MSSA) strains are usually treated with drugs in the ss-lactam class, such as cephalosporins, oxacillin or nafcillin, MRSA infections are treated with drugs in other antimicrobial classes.	ss-lactam	114-123	solute carrier family 9 member A6	Homo sapiens	179-183
27733516-0	2017	Increasing resistance to fusidic acid among clinical isolates of MRSA.	Fusidic Acid	25-37	solute carrier family 9 member A6	Homo sapiens	65-69
28900682-4	2017	These MRSA isolates, resistant to nearly all ss-lactam antimicrobials, were first largely confined to the health care environment and the patients who attended it.	ss-lactam	45-54	solute carrier family 9 member A6	Homo sapiens	6-10
28900682-7	2017	While infections caused by methicillin-susceptible S. aureus (MSSA) strains are usually treated with drugs in the ss-lactam class, such as cephalosporins, oxacillin or nafcillin, MRSA infections are treated with drugs in other antimicrobial classes.	Cephalosporins	139-153	solute carrier family 9 member A6	Homo sapiens	179-183
27494923-0	2016	Molecular basis of rifampicin resistance in multiresistant porcine livestock-associated MRSA.	Rifampin	19-29	solute carrier family 9 member A6	Homo sapiens	88-92
28900682-6	2017	CA-MRSA organisms, compared with health care-associated (HA-) MRSA strain types, are more often susceptible to multiple classes of non ss-lactam antimicrobials.	Lactams	138-144	solute carrier family 9 member A6	Homo sapiens	3-7
28900682-6	2017	CA-MRSA organisms, compared with health care-associated (HA-) MRSA strain types, are more often susceptible to multiple classes of non ss-lactam antimicrobials.	Lactams	138-144	solute carrier family 9 member A6	Homo sapiens	62-66
28900682-7	2017	While infections caused by methicillin-susceptible S. aureus (MSSA) strains are usually treated with drugs in the ss-lactam class, such as cephalosporins, oxacillin or nafcillin, MRSA infections are treated with drugs in other antimicrobial classes.	Methicillin	27-38	solute carrier family 9 member A6	Homo sapiens	179-183
26431268-0	2016	Role of linezolid therapeutic drug monitoring in the treatment of MRSA tracheo-pulmonary infection in a 10-month-old infant.	Linezolid	8-17	solute carrier family 9 member A6	Homo sapiens	66-70
27741342-11	2016	CONCLUSION: Topical minocycline foam may be a safe and effective new treatment option for impetigo in children, including those with MRSA.	Minocycline	20-31	solute carrier family 9 member A6	Homo sapiens	133-137
27590723-4	2016	METHODS: Here, we examined the molecular and cellular consequences of a 6 base-pair deletion of amino acids Glu(287) and Ser(288) ( ES) in the predicted seventh transmembrane helix of human NHE6 expressed in established cell lines (CHO/AP-1, HeLa and neuroblastoma SH-SY5Y) and primary cultures of mouse hippocampal neurons by measuring levels of protein expression, stability, membrane trafficking, endosomal function and cell viability.	Glutamic Acid	108-111	solute carrier family 9 member A6	Homo sapiens	190-194
27590723-4	2016	METHODS: Here, we examined the molecular and cellular consequences of a 6 base-pair deletion of amino acids Glu(287) and Ser(288) ( ES) in the predicted seventh transmembrane helix of human NHE6 expressed in established cell lines (CHO/AP-1, HeLa and neuroblastoma SH-SY5Y) and primary cultures of mouse hippocampal neurons by measuring levels of protein expression, stability, membrane trafficking, endosomal function and cell viability.	Einsteinium	132-134	solute carrier family 9 member A6	Homo sapiens	190-194
30108790-2	2017	This rapid synthesis permitted the discovery of novel biofilm-eradicating halogenated quinolines (MBECs = 1.0-23.5 muM) active against MRSA, MRSE, and VRE.	Quinolines	86-96	solute carrier family 9 member A6	Homo sapiens	135-139
27347712-5	2016	EXPERT OPINION: There are several promising compounds on their way, as tedizolid-a new oxazolidone, iclaprim-a novel drug, related to trimethoprim, plazomicin-a new aminoglycoside and two combinations of ceftazidime/avibactam and ceftolozane/tazobactam against MDR bacteria, especially against MRSA and Gram-negative ESBL bacteria.	tedizolid-a	71-82	solute carrier family 9 member A6	Homo sapiens	294-298
27347712-5	2016	EXPERT OPINION: There are several promising compounds on their way, as tedizolid-a new oxazolidone, iclaprim-a novel drug, related to trimethoprim, plazomicin-a new aminoglycoside and two combinations of ceftazidime/avibactam and ceftolozane/tazobactam against MDR bacteria, especially against MRSA and Gram-negative ESBL bacteria.	Oxazolidinones	87-98	solute carrier family 9 member A6	Homo sapiens	294-298
27347712-5	2016	EXPERT OPINION: There are several promising compounds on their way, as tedizolid-a new oxazolidone, iclaprim-a novel drug, related to trimethoprim, plazomicin-a new aminoglycoside and two combinations of ceftazidime/avibactam and ceftolozane/tazobactam against MDR bacteria, especially against MRSA and Gram-negative ESBL bacteria.	iclaprim-a	100-110	solute carrier family 9 member A6	Homo sapiens	294-298
27347712-5	2016	EXPERT OPINION: There are several promising compounds on their way, as tedizolid-a new oxazolidone, iclaprim-a novel drug, related to trimethoprim, plazomicin-a new aminoglycoside and two combinations of ceftazidime/avibactam and ceftolozane/tazobactam against MDR bacteria, especially against MRSA and Gram-negative ESBL bacteria.	Trimethoprim	134-146	solute carrier family 9 member A6	Homo sapiens	294-298
27347712-5	2016	EXPERT OPINION: There are several promising compounds on their way, as tedizolid-a new oxazolidone, iclaprim-a novel drug, related to trimethoprim, plazomicin-a new aminoglycoside and two combinations of ceftazidime/avibactam and ceftolozane/tazobactam against MDR bacteria, especially against MRSA and Gram-negative ESBL bacteria.	plazomicin-a	148-160	solute carrier family 9 member A6	Homo sapiens	294-298
27347712-5	2016	EXPERT OPINION: There are several promising compounds on their way, as tedizolid-a new oxazolidone, iclaprim-a novel drug, related to trimethoprim, plazomicin-a new aminoglycoside and two combinations of ceftazidime/avibactam and ceftolozane/tazobactam against MDR bacteria, especially against MRSA and Gram-negative ESBL bacteria.	Aminoglycosides	165-179	solute carrier family 9 member A6	Homo sapiens	294-298
27073268-0	2016	Linezolid-resistant cfr-positive MRSA, Italy.	Linezolid	0-9	solute carrier family 9 member A6	Homo sapiens	33-37
27307987-5	2016	The protocol makes use of polyhexanide-based products, in view of reported qac-mediated resistance to chlorhexidine in S. aureus and MRSA.	polihexanide	26-38	solute carrier family 9 member A6	Homo sapiens	133-137
27216998-0	2016	Caged xanthones: Potent inhibitors of global predominant MRSA USA300.	Xanthones	6-15	solute carrier family 9 member A6	Homo sapiens	57-61
26949849-2	2016	Following the combined use of octenilin Wound Gel and octenilin Wound Irrigation Solution, the MRSA was removed in 4 weeks, the necrotic tissue was debrided and the wound started healing.	octenilin	54-63	solute carrier family 9 member A6	Homo sapiens	95-99
27154505-6	2016	PKS type-I gene detection and chromatographic strategy yielded a robust polyketide antimicrobial compound which identified as nocapyrone E. Minimum inhibitory concentration of the purified compound against MRSA and other human pathogens ranged between 25 and 100 mug/ml.	nocapyrone S	126-136	solute carrier family 9 member A6	Homo sapiens	206-210
27022790-2	2016	MATERIALS AND METHODS: Nasal samples were taken from anterior nares were cultured in CHROMagar S. aureus plates, MRSA was determined by disc diffusion method (cefoxitin 30 mug) according to the Clinical and Laboratory Standards Institute guidelines and CHROMagar MRSA plates.	Cefoxitin	159-168	solute carrier family 9 member A6	Homo sapiens	113-117
26899719-6	2016	The gentamicin, vancomycin, amikacin and ceftriaxone beads all inhibited growth of the MRSA on the TSB and agar plates, both before and after gas sterilisation.	Gentamicins	4-14	solute carrier family 9 member A6	Homo sapiens	87-91
26899719-6	2016	The gentamicin, vancomycin, amikacin and ceftriaxone beads all inhibited growth of the MRSA on the TSB and agar plates, both before and after gas sterilisation.	Vancomycin	16-26	solute carrier family 9 member A6	Homo sapiens	87-91
26899719-6	2016	The gentamicin, vancomycin, amikacin and ceftriaxone beads all inhibited growth of the MRSA on the TSB and agar plates, both before and after gas sterilisation.	Amikacin	28-36	solute carrier family 9 member A6	Homo sapiens	87-91
26899719-6	2016	The gentamicin, vancomycin, amikacin and ceftriaxone beads all inhibited growth of the MRSA on the TSB and agar plates, both before and after gas sterilisation.	Ceftriaxone	41-52	solute carrier family 9 member A6	Homo sapiens	87-91
26899719-6	2016	The gentamicin, vancomycin, amikacin and ceftriaxone beads all inhibited growth of the MRSA on the TSB and agar plates, both before and after gas sterilisation.	Tri S Bond	99-102	solute carrier family 9 member A6	Homo sapiens	87-91
26899719-6	2016	The gentamicin, vancomycin, amikacin and ceftriaxone beads all inhibited growth of the MRSA on the TSB and agar plates, both before and after gas sterilisation.	Agar	107-111	solute carrier family 9 member A6	Homo sapiens	87-91
26565015-1	2016	MRSA bacteraemia (MRSAB), including infective endocarditis, carries a high mortality rate, with up to 50% of patients failing initial therapy with vancomycin and requiring salvage therapy.	Vancomycin	147-157	solute carrier family 9 member A6	Homo sapiens	0-4
26782772-0	2016	Novel adjuvant strategy to potentiate bacitracin against MDR MRSA.	Bacitracin	38-48	solute carrier family 9 member A6	Homo sapiens	61-65
26782772-2	2016	However, bacitracin resistance is highly prevalent in community-associated MRSA (CA-MRSA) strains and significantly compromises the effectiveness of existing antimicrobial ointments.	Bacitracin	9-19	solute carrier family 9 member A6	Homo sapiens	75-79
26782772-2	2016	However, bacitracin resistance is highly prevalent in community-associated MRSA (CA-MRSA) strains and significantly compromises the effectiveness of existing antimicrobial ointments.	Bacitracin	9-19	solute carrier family 9 member A6	Homo sapiens	84-88
26782772-4	2016	METHODS: The growth of MRSA USA300, the predominant CA-MRSA strain in the USA, was determined in the presence of bacitracin and alkyl gallates at various concentrations.	bacitracin and alkyl gallates	113-142	solute carrier family 9 member A6	Homo sapiens	23-27
26782772-5	2016	The viability of USA300 and MDR clinical isolates of MRSA was measured after exposure to various combinations of bacitracin and alkyl gallates.	Bacitracin	113-123	solute carrier family 9 member A6	Homo sapiens	53-57
26782772-5	2016	The viability of USA300 and MDR clinical isolates of MRSA was measured after exposure to various combinations of bacitracin and alkyl gallates.	alkyl gallates	128-142	solute carrier family 9 member A6	Homo sapiens	53-57
26782772-9	2016	Furthermore, bacitracin/OG combinations demonstrated similar levels of antimicrobial activity against human clinical isolates of MRSA resistant to multiple antibiotics of clinical importance.	Bacitracin	13-23	solute carrier family 9 member A6	Homo sapiens	129-133
26782772-9	2016	Furthermore, bacitracin/OG combinations demonstrated similar levels of antimicrobial activity against human clinical isolates of MRSA resistant to multiple antibiotics of clinical importance.	octyl gallate	24-26	solute carrier family 9 member A6	Homo sapiens	129-133
26782772-10	2016	CONCLUSIONS: Some alkyl gallates, particularly OG, significantly increased the antimicrobial activity of bacitracin against MDR MRSA.	alkyl gallates	18-32	solute carrier family 9 member A6	Homo sapiens	128-132
26782772-10	2016	CONCLUSIONS: Some alkyl gallates, particularly OG, significantly increased the antimicrobial activity of bacitracin against MDR MRSA.	octyl gallate	47-49	solute carrier family 9 member A6	Homo sapiens	128-132
26782772-10	2016	CONCLUSIONS: Some alkyl gallates, particularly OG, significantly increased the antimicrobial activity of bacitracin against MDR MRSA.	Bacitracin	105-115	solute carrier family 9 member A6	Homo sapiens	128-132
26849655-8	2016	CONCLUSIONS: Application of the MRSA S&D policy saves lives and money, although the high rate of unexpected MRSA cases is alarming.	Adenosine Monophosphate	39-42	solute carrier family 9 member A6	Homo sapiens	32-36
25764306-4	2015	Because her partner appeared to have solitary MRSA carriage on the glans, a suggestion of sexual transmission was made.	glans	67-72	solute carrier family 9 member A6	Homo sapiens	46-50
27528869-5	2016	Patients carrying MSSA and MRSA were treated preoperatively with mupirocin and vancomycin, respectively, along with the standard preoperative antibiotics and chlorhexidine body wipes.	Mupirocin	65-74	solute carrier family 9 member A6	Homo sapiens	27-31
27528869-5	2016	Patients carrying MSSA and MRSA were treated preoperatively with mupirocin and vancomycin, respectively, along with the standard preoperative antibiotics and chlorhexidine body wipes.	Vancomycin	79-89	solute carrier family 9 member A6	Homo sapiens	27-31
26421989-0	2015	Successful Treatment of Electrographic Status Epilepticus of Sleep With Felbamate in a Patient With SLC9A6 Mutation.	Felbamate	72-81	solute carrier family 9 member A6	Homo sapiens	100-106
26338047-0	2015	Impact of mupirocin resistance on the transmission and control of healthcare-associated MRSA.	Mupirocin	10-19	solute carrier family 9 member A6	Homo sapiens	88-92
26338047-6	2015	The total prevalence of MupR in colonized and infected MRSA patients after 5 years of simulation was 9.1% (95% CI 8.7%-9.6%) with the "screen and treat" mupirocin policy, increasing to 21.3% (95% CI 20.9%-21.7%) with "universal" mupirocin use.	Mupirocin	153-162	solute carrier family 9 member A6	Homo sapiens	55-59
26414088-0	2015	Halogenated quinolines discovered through reductive amination with potent eradication activities against MRSA, MRSE and VRE biofilms.	Quinolines	12-22	solute carrier family 9 member A6	Homo sapiens	105-109
26414088-2	2015	Here, we report the discovery of several halogenated quinolines (HQs) identified through a reductive amination reaction that demonstrated potent eradication of MRSA (HQ-6; MBEC = 125 muM), MRSE (HQ-3; MBEC = 3.0 muM) and VRE (HQ-4, HQ-5 and HQ-6; MBEC = 1.0 muM) biofilms.	Quinolines	53-63	solute carrier family 9 member A6	Homo sapiens	160-164
26142407-6	2015	Among MRSA isolates, the presence of the qacA and/or qacB gene, encoding resistance to chlorhexidine, ranges from 65% to 91%, which, along with mupirocin resistance, is associated with failed decolonization.	Chlorhexidine	87-100	solute carrier family 9 member A6	Homo sapiens	6-10
26142407-0	2015	Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA.	Mupirocin	0-9	solute carrier family 9 member A6	Homo sapiens	94-98
26142407-6	2015	Among MRSA isolates, the presence of the qacA and/or qacB gene, encoding resistance to chlorhexidine, ranges from 65% to 91%, which, along with mupirocin resistance, is associated with failed decolonization.	Mupirocin	144-153	solute carrier family 9 member A6	Homo sapiens	6-10
26142407-1	2015	Mupirocin 2% ointment is used either alone or with skin antiseptics as part of a comprehensive MRSA decolonization strategy.	Mupirocin	0-9	solute carrier family 9 member A6	Homo sapiens	95-99
26142407-2	2015	Increased mupirocin use predisposes to mupirocin resistance, which is significantly associated with persistent MRSA carriage.	Mupirocin	10-19	solute carrier family 9 member A6	Homo sapiens	111-115
26026664-4	2015	Segregated analysis of the results depending on the origin of the isolates (clinical, animal, and food) revealed a significant lower performance in the MRSA confirmation of food-derived isolates by using Brilliance MRSA 2 agar in comparison to PCR confirmation (p = 0.003) or ChromID MRSA agar (p<0.001).	Agar	222-226	solute carrier family 9 member A6	Homo sapiens	152-156
26142407-2	2015	Increased mupirocin use predisposes to mupirocin resistance, which is significantly associated with persistent MRSA carriage.	Mupirocin	39-48	solute carrier family 9 member A6	Homo sapiens	111-115
26026664-4	2015	Segregated analysis of the results depending on the origin of the isolates (clinical, animal, and food) revealed a significant lower performance in the MRSA confirmation of food-derived isolates by using Brilliance MRSA 2 agar in comparison to PCR confirmation (p = 0.003) or ChromID MRSA agar (p<0.001).	Agar	222-226	solute carrier family 9 member A6	Homo sapiens	215-219
26026664-4	2015	Segregated analysis of the results depending on the origin of the isolates (clinical, animal, and food) revealed a significant lower performance in the MRSA confirmation of food-derived isolates by using Brilliance MRSA 2 agar in comparison to PCR confirmation (p = 0.003) or ChromID MRSA agar (p<0.001).	Agar	222-226	solute carrier family 9 member A6	Homo sapiens	215-219
26258318-9	2015	Gram-positive related infections and MRSA infections occurred in 1(1.18%)/0(0%) of Vancomycin patients and 9 (9.68%)/1 (1.08%) of Daptomycin patients, respectively (P < 0.02 and P = 1.00).	Vancomycin	83-93	solute carrier family 9 member A6	Homo sapiens	37-41
26258318-9	2015	Gram-positive related infections and MRSA infections occurred in 1(1.18%)/0(0%) of Vancomycin patients and 9 (9.68%)/1 (1.08%) of Daptomycin patients, respectively (P < 0.02 and P = 1.00).	Daptomycin	130-140	solute carrier family 9 member A6	Homo sapiens	37-41
26198370-2	2015	We conducted a real-world analysis of antibiotic treatment, hospital resource use and clinical outcomes in patients with PVD and/or diabetes receiving linezolid or vancomycin for the treatment of methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections (MRSA cSSTIs) across Europe.	Linezolid	151-160	solute carrier family 9 member A6	Homo sapiens	285-289
26273719-1	2015	Total Synthesis of MRSA-Active Tetarimycin A and Its Analogues.	tetarimycin A	31-44	solute carrier family 9 member A6	Homo sapiens	19-23
26273719-3	2015	Preliminary SAR not only validated that tetarimycin A exhibited potent activity against MRSA and VRE at a low MIC value but also identified that the hydroxyl group at C-10 was essential for antibacterial activities.	tetarimycin A	40-53	solute carrier family 9 member A6	Homo sapiens	88-92
26198370-2	2015	We conducted a real-world analysis of antibiotic treatment, hospital resource use and clinical outcomes in patients with PVD and/or diabetes receiving linezolid or vancomycin for the treatment of methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections (MRSA cSSTIs) across Europe.	Vancomycin	164-174	solute carrier family 9 member A6	Homo sapiens	285-289
26198370-9	2015	The reduction in resource use may result in lower hospital costs for patients with PVD and/or diabetes and MRSA cSSTIs if treated with linezolid compared with vancomycin.	Linezolid	135-144	solute carrier family 9 member A6	Homo sapiens	107-111
26048876-9	2015	Moreover, for the first time the qacG and qacJ genes were detected in MRSA CC398 strains.	qacg	33-37	solute carrier family 9 member A6	Homo sapiens	70-74
26305895-11	2015	The drop in MRSA prevalence in people during the study could be attributed to the observed long-term AMU decreasing trend.	N-acetyl-beta-muramic acid	101-104	solute carrier family 9 member A6	Homo sapiens	12-16
25904727-1	2015	OBJECTIVES: The antimicrobial efficacy of an iodine-impregnated incise drape against MRSA was evaluated in a skin model.	Iodine	45-51	solute carrier family 9 member A6	Homo sapiens	85-89
25904727-7	2015	Furthermore, in experiments wherein a high inoculum of MRSA was applied with no pre-incubation period, the iodine-impregnated drape demonstrated superior antimicrobial activity compared with the use of a non-antimicrobial drape (P < 0.001).	Iodine	107-113	solute carrier family 9 member A6	Homo sapiens	55-59
24313336-5	2015	Moreover, Mrs A"s accuracy scores on the n-back task (i.e., 2-back condition) improved from 79% (baseline) to 96% (after DTMS treatment).	dtms	121-125	solute carrier family 9 member A6	Homo sapiens	10-15
25977400-0	2015	Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia.	T 91825	22-33	solute carrier family 9 member A6	Homo sapiens	74-78
25246437-0	2015	The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.	T 91825	19-30	solute carrier family 9 member A6	Homo sapiens	115-119
25966789-0	2015	Emodin is identified as the active component of ether extracts from Rhizoma Polygoni Cuspidati, for anti-MRSA activity.	Ether	48-53	solute carrier family 9 member A6	Homo sapiens	105-109
25561733-5	2015	The Na(+)/H(+) exchanger NHE6 provides a leak pathway for protons, limiting luminal acidification by proton pumps.	Phenobarbital	76-83	solute carrier family 9 member A6	Homo sapiens	25-29
25246437-0	2015	The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.	Daptomycin	36-46	solute carrier family 9 member A6	Homo sapiens	115-119
25246437-1	2015	OBJECTIVES: We previously demonstrated that ceftaroline enhances daptomycin against MRSA in vitro.	T 91825	44-55	solute carrier family 9 member A6	Homo sapiens	84-88
25246437-1	2015	OBJECTIVES: We previously demonstrated that ceftaroline enhances daptomycin against MRSA in vitro.	Daptomycin	65-75	solute carrier family 9 member A6	Homo sapiens	84-88
25246437-10	2015	CONCLUSIONS: These findings confirm that ceftaroline+daptomycin is a potent combination against MRSA.	T 91825	41-52	solute carrier family 9 member A6	Homo sapiens	96-100
25246437-10	2015	CONCLUSIONS: These findings confirm that ceftaroline+daptomycin is a potent combination against MRSA.	Daptomycin	53-63	solute carrier family 9 member A6	Homo sapiens	96-100
24313336-6	2015	At the neural level, Mrs A showed significantly increased brain activity in the working memory network (e.g., DLPFC, parietal cortex) during the execution of the 2-back condition after DTMS treatment compared to baseline.	dtms	185-189	solute carrier family 9 member A6	Homo sapiens	21-26
26168679-4	2015	The highest levels of the MRSA resistance were stated against ciprofloxacin--92%(MIC50 32 mcg/ml), gentamicin--85% (MIC50 128 mcg/ml), erythromycin--54% (MIC50 32-mcg/ml) and clindainycin - 45% (MIC50 0.03 mcg/ml), as well as against rifampicin--38% (MIC50 0.06 mcg/ml).	Ciprofloxacin	62-75	solute carrier family 9 member A6	Homo sapiens	26-30
27141645-0	2015	[Results of Investigation of MRSA Susceptibility to Vancomycin in Clinical Units of Large Multifunctional Hospital and Recommendations on Optimization of Antibacterial Therapy of Staphylococcal Infection].	Vancomycin	52-62	solute carrier family 9 member A6	Homo sapiens	29-33
25672426-1	2015	OBJECTIVE: To establish the risk factors for joint infection by oxacillin-resistant Staphylococcus aureus (MRSA) using clinical and epidemiological data.	Oxacillin	64-73	solute carrier family 9 member A6	Homo sapiens	107-111
25209610-0	2015	Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection.	Trimethoprim, Sulfamethoxazole Drug Combination	44-73	solute carrier family 9 member A6	Homo sapiens	128-132
25209610-0	2015	Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection.	Linezolid	97-106	solute carrier family 9 member A6	Homo sapiens	128-132
25209610-2	2015	The aim of this study was to assess the non-inferiority of a combination of trimethoprim/sulfamethoxazole plus rifampicin versus linezolid alone for the treatment of MRSA infection.	Trimethoprim, Sulfamethoxazole Drug Combination	76-105	solute carrier family 9 member A6	Homo sapiens	166-170
25209610-2	2015	The aim of this study was to assess the non-inferiority of a combination of trimethoprim/sulfamethoxazole plus rifampicin versus linezolid alone for the treatment of MRSA infection.	Rifampin	111-121	solute carrier family 9 member A6	Homo sapiens	166-170
25209610-13	2015	CONCLUSIONS: Compared with linezolid, trimethoprim/sulfamethoxazole and rifampicin seems to be non-inferior in the treatment of MRSA infection.	Trimethoprim, Sulfamethoxazole Drug Combination	38-67	solute carrier family 9 member A6	Homo sapiens	128-132
25209610-13	2015	CONCLUSIONS: Compared with linezolid, trimethoprim/sulfamethoxazole and rifampicin seems to be non-inferior in the treatment of MRSA infection.	Rifampin	72-82	solute carrier family 9 member A6	Homo sapiens	128-132
26168679-4	2015	The highest levels of the MRSA resistance were stated against ciprofloxacin--92%(MIC50 32 mcg/ml), gentamicin--85% (MIC50 128 mcg/ml), erythromycin--54% (MIC50 32-mcg/ml) and clindainycin - 45% (MIC50 0.03 mcg/ml), as well as against rifampicin--38% (MIC50 0.06 mcg/ml).	Gentamicins	99-109	solute carrier family 9 member A6	Homo sapiens	26-30
27141645-4	2015	The use of the E-test for MRSA susceptibility to vancomycin allowed to estimate the validity of the use of various antibiotics active against MRSA in the treatment of inpatients and to reduce the risk of ineffective therapy.	Vancomycin	49-59	solute carrier family 9 member A6	Homo sapiens	26-30
27141645-4	2015	The use of the E-test for MRSA susceptibility to vancomycin allowed to estimate the validity of the use of various antibiotics active against MRSA in the treatment of inpatients and to reduce the risk of ineffective therapy.	Vancomycin	49-59	solute carrier family 9 member A6	Homo sapiens	142-146
26168679-4	2015	The highest levels of the MRSA resistance were stated against ciprofloxacin--92%(MIC50 32 mcg/ml), gentamicin--85% (MIC50 128 mcg/ml), erythromycin--54% (MIC50 32-mcg/ml) and clindainycin - 45% (MIC50 0.03 mcg/ml), as well as against rifampicin--38% (MIC50 0.06 mcg/ml).	Erythromycin	135-147	solute carrier family 9 member A6	Homo sapiens	26-30
26168679-4	2015	The highest levels of the MRSA resistance were stated against ciprofloxacin--92%(MIC50 32 mcg/ml), gentamicin--85% (MIC50 128 mcg/ml), erythromycin--54% (MIC50 32-mcg/ml) and clindainycin - 45% (MIC50 0.03 mcg/ml), as well as against rifampicin--38% (MIC50 0.06 mcg/ml).	clindainycin	175-187	solute carrier family 9 member A6	Homo sapiens	26-30
26168679-4	2015	The highest levels of the MRSA resistance were stated against ciprofloxacin--92%(MIC50 32 mcg/ml), gentamicin--85% (MIC50 128 mcg/ml), erythromycin--54% (MIC50 32-mcg/ml) and clindainycin - 45% (MIC50 0.03 mcg/ml), as well as against rifampicin--38% (MIC50 0.06 mcg/ml).	Rifampin	234-244	solute carrier family 9 member A6	Homo sapiens	26-30
26168679-5	2015	The frequency of MRSA isolated at the vancomycin dose of 2 mcg/ml equaled 26%.	Vancomycin	38-48	solute carrier family 9 member A6	Homo sapiens	17-21
26168679-7	2015	In 5% of MRSA isolated from infected surgical wounds in patients with bone infection or sepsis, there was observed a decrease in the susceptibility to ceftarolin (MIC 2-4 mcg/ml).	ceftarolin	151-161	solute carrier family 9 member A6	Homo sapiens	9-13
24831298-1	2015	Mrs A, a 68-year-old woman with paranoid schizophrenia, was on long-term psychiatric treatment with long-acting intramuscular zuclopenthixol, quetiapine and alprazolam when, in April 2012, she was diagnosed with right breast infiltrating ductal carcinoma.	Clopenthixol	126-140	solute carrier family 9 member A6	Homo sapiens	0-5
24831298-1	2015	Mrs A, a 68-year-old woman with paranoid schizophrenia, was on long-term psychiatric treatment with long-acting intramuscular zuclopenthixol, quetiapine and alprazolam when, in April 2012, she was diagnosed with right breast infiltrating ductal carcinoma.	Quetiapine Fumarate	142-152	solute carrier family 9 member A6	Homo sapiens	0-5
24831298-1	2015	Mrs A, a 68-year-old woman with paranoid schizophrenia, was on long-term psychiatric treatment with long-acting intramuscular zuclopenthixol, quetiapine and alprazolam when, in April 2012, she was diagnosed with right breast infiltrating ductal carcinoma.	Alprazolam	157-167	solute carrier family 9 member A6	Homo sapiens	0-5
24831298-2	2015	After starting treatment with letrozole on 4 July, Mrs A progressively developed extrapyramidal symptoms and these were particularly evident after each zuclopenthixol administration.	Letrozole	30-39	solute carrier family 9 member A6	Homo sapiens	51-56
24831298-2	2015	After starting treatment with letrozole on 4 July, Mrs A progressively developed extrapyramidal symptoms and these were particularly evident after each zuclopenthixol administration.	Clopenthixol	152-166	solute carrier family 9 member A6	Homo sapiens	51-56
25103488-2	2014	OBJECTIVES: After the implementation of an active surveillance programme for MRSA in US Veterans Affairs (VA) Medical Centers, there was an increase in vancomycin use.	Vancomycin	152-162	solute carrier family 9 member A6	Homo sapiens	77-81
24934663-8	2015	A combination of rifampin and clarithromycin released from the polymer film provided >99.9% kill of an MRSA inoculate for up to 72 h. CONCLUSION: Results showed that combining multiple drugs in copolymer films with unique surface properties, initial hydrophilicity and increase in roughness, can be an effective way to prevent biofilm formation.	Rifampin	17-25	solute carrier family 9 member A6	Homo sapiens	106-110
24934663-8	2015	A combination of rifampin and clarithromycin released from the polymer film provided >99.9% kill of an MRSA inoculate for up to 72 h. CONCLUSION: Results showed that combining multiple drugs in copolymer films with unique surface properties, initial hydrophilicity and increase in roughness, can be an effective way to prevent biofilm formation.	Clarithromycin	30-44	solute carrier family 9 member A6	Homo sapiens	106-110
24934663-8	2015	A combination of rifampin and clarithromycin released from the polymer film provided >99.9% kill of an MRSA inoculate for up to 72 h. CONCLUSION: Results showed that combining multiple drugs in copolymer films with unique surface properties, initial hydrophilicity and increase in roughness, can be an effective way to prevent biofilm formation.	copolymer	197-206	solute carrier family 9 member A6	Homo sapiens	106-110
25288400-7	2015	Forty-one percent of S. aureus strains isolated in all the patients were resistant to methicillin (MRSA).	Methicillin	86-97	solute carrier family 9 member A6	Homo sapiens	99-103
25429539-0	2014	[Zinforo  (ceftaroline fosamil)--A new beta-lactam-cephalosporin with MRSA activity].	Ceftaroline fosamil acetate	1-8	solute carrier family 9 member A6	Homo sapiens	70-74
25429539-0	2014	[Zinforo  (ceftaroline fosamil)--A new beta-lactam-cephalosporin with MRSA activity].	ceftaroline fosamil	11-30	solute carrier family 9 member A6	Homo sapiens	70-74
25429539-0	2014	[Zinforo  (ceftaroline fosamil)--A new beta-lactam-cephalosporin with MRSA activity].	beta-lactam-cephalosporin	39-64	solute carrier family 9 member A6	Homo sapiens	70-74
24090639-11	2014	These results suggest that deletion of (370)Trp-Ser-Thr(372) leads to endoplasmic reticulum retention and loss of NHE6 function which potentially impacts the trafficking of other membrane-bound cargo and cell polarity.	Threonine	52-55	solute carrier family 9 member A6	Homo sapiens	114-118
25137207-4	2014	In addition to MRSA, the greatest danger in relation to antibiotic resistance worldwide are now considered tob e carbapenem-resistant Enterobacteriaceae (CRE) or multidrug-resistant Gram-negative (4MRGN) bacteria.	Carbapenems	113-123	solute carrier family 9 member A6	Homo sapiens	15-19
24816900-10	2014	CA-MRSA decontamination using mupirocin and chlorhexidine in the community setting may also be a questionable strategy, associated with failure and resistance to both agents.	Mupirocin	30-39	solute carrier family 9 member A6	Homo sapiens	3-7
24816900-10	2014	CA-MRSA decontamination using mupirocin and chlorhexidine in the community setting may also be a questionable strategy, associated with failure and resistance to both agents.	Chlorhexidine	44-57	solute carrier family 9 member A6	Homo sapiens	3-7
24239015-0	2013	Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.	bis(bibenzyl)	57-70	solute carrier family 9 member A6	Homo sapiens	15-19
24885158-11	2014	Most MRSA patients (66%, 88/134) were treated empirically (primarily vancomycin) but outcome was not improved by receipt of empiric therapy.	Vancomycin	69-79	solute carrier family 9 member A6	Homo sapiens	5-9
24239015-2	2013	The structure-activity relationships and the results of molecular dynamics simulations indicated that bis(bibenzyl)s with potent anti-MRSA activity commonly have a 4-hydroxyl group at the D-benzene ring and a 2-hydroxyl group at the C-benzene ring in the hydrophilic part of the molecule, and an unsubstituted phenoxyphenyl group in the hydrophobic part of the molecule containing the A-B-benzene rings.	bis(bibenzyl)s	102-116	solute carrier family 9 member A6	Homo sapiens	134-138
24239015-2	2013	The structure-activity relationships and the results of molecular dynamics simulations indicated that bis(bibenzyl)s with potent anti-MRSA activity commonly have a 4-hydroxyl group at the D-benzene ring and a 2-hydroxyl group at the C-benzene ring in the hydrophilic part of the molecule, and an unsubstituted phenoxyphenyl group in the hydrophobic part of the molecule containing the A-B-benzene rings.	Deuterium	188-189	solute carrier family 9 member A6	Homo sapiens	134-138
25000521-4	2014	To test this, we identified the proportion of MC398 in MRSA positive individuals without contact with pigs/veal calves or other known risk factors (MRSA of unknown origin; MUO).	mc398	46-51	solute carrier family 9 member A6	Homo sapiens	55-59
24668837-0	2014	Teicoplanin for treating MRSA pneumonia.	Teicoplanin	0-11	solute carrier family 9 member A6	Homo sapiens	25-29
24165181-1	2014	The purpose of this study was to compare the clinical efficacy and safety of vancomycin to those of teicoplanin for the treatment of adult patients with health care-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) bacteremia.	Vancomycin	77-87	solute carrier family 9 member A6	Homo sapiens	224-228
24165181-10	2014	This study indicates that teicoplanin is an effective and safe alternative to vancomycin for the treatment of HA-MRSA bacteremia.	Teicoplanin	26-37	solute carrier family 9 member A6	Homo sapiens	113-117
23499479-7	2013	The incidence of fluoroquinolone resistance in HA-MRSA is remarkably high, suggesting use of this class of antibiotics as well as the beta-lactams contributes to the selection and success of HA-MRSA clones in the hospital setting.	Fluoroquinolones	17-32	solute carrier family 9 member A6	Homo sapiens	50-54
24063393-0	2013	GenomEra MRSA/SA, a fully automated homogeneous PCR assay for rapid detection of Staphylococcus aureus and the marker of methicillin resistance in various sample matrixes.	Methicillin	121-132	solute carrier family 9 member A6	Homo sapiens	9-13
24063393-3	2013	It can be used for both screening and confirmation of methicillin-resistant and -sensitive S. aureus (MRSA and MSSA) directly in different specimen types or from preceding cultures.	Methicillin	54-65	solute carrier family 9 member A6	Homo sapiens	102-106
24239015-2	2013	The structure-activity relationships and the results of molecular dynamics simulations indicated that bis(bibenzyl)s with potent anti-MRSA activity commonly have a 4-hydroxyl group at the D-benzene ring and a 2-hydroxyl group at the C-benzene ring in the hydrophilic part of the molecule, and an unsubstituted phenoxyphenyl group in the hydrophobic part of the molecule containing the A-B-benzene rings.	Benzene	190-197	solute carrier family 9 member A6	Homo sapiens	134-138
24239015-2	2013	The structure-activity relationships and the results of molecular dynamics simulations indicated that bis(bibenzyl)s with potent anti-MRSA activity commonly have a 4-hydroxyl group at the D-benzene ring and a 2-hydroxyl group at the C-benzene ring in the hydrophilic part of the molecule, and an unsubstituted phenoxyphenyl group in the hydrophobic part of the molecule containing the A-B-benzene rings.	Benzene	235-242	solute carrier family 9 member A6	Homo sapiens	134-138
24239015-2	2013	The structure-activity relationships and the results of molecular dynamics simulations indicated that bis(bibenzyl)s with potent anti-MRSA activity commonly have a 4-hydroxyl group at the D-benzene ring and a 2-hydroxyl group at the C-benzene ring in the hydrophilic part of the molecule, and an unsubstituted phenoxyphenyl group in the hydrophobic part of the molecule containing the A-B-benzene rings.	Benzene	235-242	solute carrier family 9 member A6	Homo sapiens	134-138
24239015-3	2013	Pharmacological characterization of the bis(bibenzyl) derivatives and 2-phenoxyphenol fragment 25, previously proposed as the minimum structure of riccardin C 1 for anti-MRSA activity, indicated that they have different action mechanisms: the bis(bibenzyl)s are bactericidal, while 25 is bacteriostatic, showing only weak bactericidal activity.	Carbon	157-158	solute carrier family 9 member A6	Homo sapiens	170-174
24260299-0	2013	Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials.	Teicoplanin	0-11	solute carrier family 9 member A6	Homo sapiens	71-75
24260299-7	2013	CONCLUSIONS: The meta-analysis results indicate that the two therapies are similar in both efficacy and safety, thus teicoplanin can act as an effective alternative to vancomycin for treating patients infected by MRSA.	Teicoplanin	117-128	solute carrier family 9 member A6	Homo sapiens	213-217
24068869-2	2013	Our objective was to develop an economic model from a US payer perspective that includes all direct inpatient and outpatient costs incurred by patients with MRSA cSSTI receiving linezolid, vancomycin, or daptomycin.	Linezolid	178-187	solute carrier family 9 member A6	Homo sapiens	157-167
24068869-2	2013	Our objective was to develop an economic model from a US payer perspective that includes all direct inpatient and outpatient costs incurred by patients with MRSA cSSTI receiving linezolid, vancomycin, or daptomycin.	Vancomycin	189-199	solute carrier family 9 member A6	Homo sapiens	157-167
24068869-2	2013	Our objective was to develop an economic model from a US payer perspective that includes all direct inpatient and outpatient costs incurred by patients with MRSA cSSTI receiving linezolid, vancomycin, or daptomycin.	Daptomycin	204-214	solute carrier family 9 member A6	Homo sapiens	157-167
24068869-13	2013	CONCLUSION: Outpatient costs of managing MRSA cSSTI may be reduced by 30%-50% with oral linezolid compared with vancomycin or daptomycin.	Linezolid	88-97	solute carrier family 9 member A6	Homo sapiens	41-51
24068869-13	2013	CONCLUSION: Outpatient costs of managing MRSA cSSTI may be reduced by 30%-50% with oral linezolid compared with vancomycin or daptomycin.	Vancomycin	112-122	solute carrier family 9 member A6	Homo sapiens	41-51
24068869-13	2013	CONCLUSION: Outpatient costs of managing MRSA cSSTI may be reduced by 30%-50% with oral linezolid compared with vancomycin or daptomycin.	Daptomycin	126-136	solute carrier family 9 member A6	Homo sapiens	41-51
23499479-7	2013	The incidence of fluoroquinolone resistance in HA-MRSA is remarkably high, suggesting use of this class of antibiotics as well as the beta-lactams contributes to the selection and success of HA-MRSA clones in the hospital setting.	Fluoroquinolones	17-32	solute carrier family 9 member A6	Homo sapiens	194-198
23499479-7	2013	The incidence of fluoroquinolone resistance in HA-MRSA is remarkably high, suggesting use of this class of antibiotics as well as the beta-lactams contributes to the selection and success of HA-MRSA clones in the hospital setting.	beta-Lactams	134-146	solute carrier family 9 member A6	Homo sapiens	50-54
23499479-7	2013	The incidence of fluoroquinolone resistance in HA-MRSA is remarkably high, suggesting use of this class of antibiotics as well as the beta-lactams contributes to the selection and success of HA-MRSA clones in the hospital setting.	beta-Lactams	134-146	solute carrier family 9 member A6	Homo sapiens	194-198
23150480-0	2012	MRSA in waste treatment water poses potential risk.	Water	24-29	solute carrier family 9 member A6	Homo sapiens	0-4
23036849-0	2013	Accurate classification of childhood brain tumours by in vivo 1H MRS - a multi-centre study.	Hydrogen	62-64	solute carrier family 9 member A6	Homo sapiens	65-72
24738238-0	2013	[Estimation of MRSA susceptibility to oxacillin, cefoxitine, vancomycin and daptomycin].	Oxacillin	38-47	solute carrier family 9 member A6	Homo sapiens	15-19
24738238-0	2013	[Estimation of MRSA susceptibility to oxacillin, cefoxitine, vancomycin and daptomycin].	Cefoxitin	49-59	solute carrier family 9 member A6	Homo sapiens	15-19
24738238-0	2013	[Estimation of MRSA susceptibility to oxacillin, cefoxitine, vancomycin and daptomycin].	Vancomycin	61-71	solute carrier family 9 member A6	Homo sapiens	15-19
24738238-0	2013	[Estimation of MRSA susceptibility to oxacillin, cefoxitine, vancomycin and daptomycin].	Daptomycin	76-86	solute carrier family 9 member A6	Homo sapiens	15-19
24738238-2	2013	Therefore, correct laboratory identification of the MRSA phenotype based on the use of the marker antibiotic cefoxitine, as a more susceptibile one vs. oxacillin, is of great importance.	Cefoxitin	109-119	solute carrier family 9 member A6	Homo sapiens	52-56
24738238-2	2013	Therefore, correct laboratory identification of the MRSA phenotype based on the use of the marker antibiotic cefoxitine, as a more susceptibile one vs. oxacillin, is of great importance.	Oxacillin	152-161	solute carrier family 9 member A6	Homo sapiens	52-56
24738238-3	2013	There is lately being observed a tendency towards emergence of strains with lower susceptibility to the last reserve drugs protecting from MRSA, i. e. vancomycin and daptomycin.	Vancomycin	151-161	solute carrier family 9 member A6	Homo sapiens	139-143
24738238-3	2013	There is lately being observed a tendency towards emergence of strains with lower susceptibility to the last reserve drugs protecting from MRSA, i. e. vancomycin and daptomycin.	Daptomycin	166-176	solute carrier family 9 member A6	Homo sapiens	139-143
24738238-5	2013	The results of our study on estimation of susceptibility of 316 MRSA isolates from several regions of Russia to oxacillin, cefoxitine, vancomycin and daptomycin are presented herein.	Oxacillin	112-121	solute carrier family 9 member A6	Homo sapiens	64-68
24738238-5	2013	The results of our study on estimation of susceptibility of 316 MRSA isolates from several regions of Russia to oxacillin, cefoxitine, vancomycin and daptomycin are presented herein.	Cefoxitin	123-133	solute carrier family 9 member A6	Homo sapiens	64-68
24738238-5	2013	The results of our study on estimation of susceptibility of 316 MRSA isolates from several regions of Russia to oxacillin, cefoxitine, vancomycin and daptomycin are presented herein.	Vancomycin	135-145	solute carrier family 9 member A6	Homo sapiens	64-68
24738238-5	2013	The results of our study on estimation of susceptibility of 316 MRSA isolates from several regions of Russia to oxacillin, cefoxitine, vancomycin and daptomycin are presented herein.	Daptomycin	150-160	solute carrier family 9 member A6	Homo sapiens	64-68
24738238-7	2013	As for cefoxitine, the MRSA isolates were rather resistant to it at the MIC > 16 mcg/ml.	Cefoxitin	7-17	solute carrier family 9 member A6	Homo sapiens	23-27
24738238-10	2013	The MRSA isolates were highly susceptible to daptomycin, while high levels of the MIC (2 mcg/ml) were characteristic of 2.8 +/- 1% of the isolates.	Daptomycin	45-55	solute carrier family 9 member A6	Homo sapiens	4-8
23936095-4	2013	The frequency of spontaneous mutants arising following exposure to fosfomycin, tobramycin and F:T was determined for clinical Pseudomonas aeruginosa and MRSA isolates under aerobic and anaerobic conditions.	Fosfomycin	67-77	solute carrier family 9 member A6	Homo sapiens	153-157
23936095-6	2013	P. aeruginosa and MRSA isolates had a lower frequency of spontaneous mutants to F:T compared to fosfomycin and tobramycin under both aerobic and anaerobic conditions.	Fosfomycin	96-106	solute carrier family 9 member A6	Homo sapiens	18-22
23936095-6	2013	P. aeruginosa and MRSA isolates had a lower frequency of spontaneous mutants to F:T compared to fosfomycin and tobramycin under both aerobic and anaerobic conditions.	Tobramycin	111-121	solute carrier family 9 member A6	Homo sapiens	18-22
22371294-1	2012	PURPOSE: To evaluate the usefulness of daptomycin, tigecycline, and linezolid for the treatment of MRSA infection compared with vancomycin in Belgium, the United Kingdom/Ireland, and Spain.	Linezolid	68-77	solute carrier family 9 member A6	Homo sapiens	99-103
22585351-3	2012	QUESTIONS/PURPOSES: We asked whether (1) C2DA inhibited MRSA growth and biofilm, (2) antibiotics increased inhibitory effects, (3) inhibitory concentrations of C2DA were cytotoxic to human cells, and (4) effective concentrations could be delivered from a chitosan sponge drug delivery device.	2-decenoic acid	41-45	solute carrier family 9 member A6	Homo sapiens	56-60
23109011-8	2012	In addition, among all tested antibiotics, vancomycin and nitrofurantion seem to be the most effective antibiotics for MR- SA.	Vancomycin	43-53	solute carrier family 9 member A6	Homo sapiens	119-125
23109011-8	2012	In addition, among all tested antibiotics, vancomycin and nitrofurantion seem to be the most effective antibiotics for MR- SA.	nitrofurantion	58-72	solute carrier family 9 member A6	Homo sapiens	119-125
22784260-8	2012	RESULTS: Of the 7,183 patients with cSSSI, 2,387 (33.2%) had MRSA.	csssi	36-41	solute carrier family 9 member A6	Homo sapiens	61-65
22399220-1	2012	OBJECTIVE: To determine epidemiology and clinical characteristics of infants with methicillin-susceptible (MSSA) and -resistant Staphylococcus aureus (MRSA) in a level III neonatal intensive care unit (NICU).	Methicillin	82-93	solute carrier family 9 member A6	Homo sapiens	151-155
22196908-6	2011	There is an increasing realisation that reducing the use of fluoroquinolones and third-generation cephalosporins (which have been associated with increased carriage of MRSA) in patient populations where MRSA is prevalent can be a useful control measure.	Fluoroquinolones	60-76	solute carrier family 9 member A6	Homo sapiens	168-172
22397861-1	2012	Preoperative screening and decolonization of methicillin-sensitive and methicillin-resistant Staphylococcus aureus (MSSA and MRSA, respectively) are advocated to reduce surgical site infections.	Methicillin	45-56	solute carrier family 9 member A6	Homo sapiens	125-129
22500244-2	2012	Although vancomycin has been considered a gold standard for the therapy of MRSA pneumonia, clinical failure rates have also been reported owing to its slow, time-dependent bactericidal activity, variable lung tissue penetration and poor intracellular penetration into macrophages.	Vancomycin	9-19	solute carrier family 9 member A6	Homo sapiens	75-79
22397861-1	2012	Preoperative screening and decolonization of methicillin-sensitive and methicillin-resistant Staphylococcus aureus (MSSA and MRSA, respectively) are advocated to reduce surgical site infections.	Methicillin	71-82	solute carrier family 9 member A6	Homo sapiens	125-129
22607475-9	2012	Transmission rates were higher in pigs treated with tetracyclins and beta-lactams compared to untreated pigs implying a selective advantage of MRSA CC398 when these antimicrobials are used.	tetracyclins	52-64	solute carrier family 9 member A6	Homo sapiens	143-147
22607475-9	2012	Transmission rates were higher in pigs treated with tetracyclins and beta-lactams compared to untreated pigs implying a selective advantage of MRSA CC398 when these antimicrobials are used.	beta-Lactams	69-81	solute carrier family 9 member A6	Homo sapiens	143-147
22301774-4	2012	Additionally some 2-aminopyrmidines were able to suppress MRSA resistance to conventional antibiotics.	2-aminopyrmidines	18-35	solute carrier family 9 member A6	Homo sapiens	58-62
22196908-6	2011	There is an increasing realisation that reducing the use of fluoroquinolones and third-generation cephalosporins (which have been associated with increased carriage of MRSA) in patient populations where MRSA is prevalent can be a useful control measure.	Fluoroquinolones	60-76	solute carrier family 9 member A6	Homo sapiens	203-207
22196908-6	2011	There is an increasing realisation that reducing the use of fluoroquinolones and third-generation cephalosporins (which have been associated with increased carriage of MRSA) in patient populations where MRSA is prevalent can be a useful control measure.	Cephalosporins	98-112	solute carrier family 9 member A6	Homo sapiens	168-172
22196908-6	2011	There is an increasing realisation that reducing the use of fluoroquinolones and third-generation cephalosporins (which have been associated with increased carriage of MRSA) in patient populations where MRSA is prevalent can be a useful control measure.	Cephalosporins	98-112	solute carrier family 9 member A6	Homo sapiens	203-207
21327600-5	2011	In all of the patients with MRSA-positive bile culture, vancomycin was prophylactically administered after surgery.	Vancomycin	56-66	solute carrier family 9 member A6	Homo sapiens	28-32
21682676-3	2011	The main regime of antibiotic treatment recommended for MRSA pneumonia is either vancomycin or linezolid.	Vancomycin	81-91	solute carrier family 9 member A6	Homo sapiens	56-60
21682676-3	2011	The main regime of antibiotic treatment recommended for MRSA pneumonia is either vancomycin or linezolid.	Linezolid	95-104	solute carrier family 9 member A6	Homo sapiens	56-60
21511410-0	2011	Decreased susceptibility of MRSA ST398 to tiamulin.	tiamulin	42-50	solute carrier family 9 member A6	Homo sapiens	28-32
21685529-10	2011	In cases of empirical administration, it is necessary to use antibiotics with high level of activity against pneumonia agents - carbapenems, and in case of high probability of MRSA - it is better to use linezolid or vancomicin.	Linezolid	203-212	solute carrier family 9 member A6	Homo sapiens	176-180
21685529-10	2011	In cases of empirical administration, it is necessary to use antibiotics with high level of activity against pneumonia agents - carbapenems, and in case of high probability of MRSA - it is better to use linezolid or vancomicin.	Vancomycin	216-226	solute carrier family 9 member A6	Homo sapiens	176-180
20714913-0	2011	An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.	Teicoplanin	29-40	solute carrier family 9 member A6	Homo sapiens	113-117
21977823-9	2011	16% of MRSA carriers develop an infection that needs to be treated with vancomycin.	Vancomycin	72-82	solute carrier family 9 member A6	Homo sapiens	7-11
21839399-2	2011	OBJECTIVE: A decision analytic (DA) model was developed to evaluate the cost-effectiveness analysis (CEA) of linezolid, daptomycin, and vancomycin in MRSA cSSSI.	Linezolid	109-118	solute carrier family 9 member A6	Homo sapiens	150-160
21839399-2	2011	OBJECTIVE: A decision analytic (DA) model was developed to evaluate the cost-effectiveness analysis (CEA) of linezolid, daptomycin, and vancomycin in MRSA cSSSI.	Vancomycin	136-146	solute carrier family 9 member A6	Homo sapiens	150-160
21839399-6	2011	Primary outcome was the incremental cost-effectiveness ratio between linezolid and vancomycin, daptomycin and vancomycin, and linezolid and daptomycin in MRSA cSSSI.	Daptomycin	140-150	solute carrier family 9 member A6	Homo sapiens	154-164
21839399-13	2011	CONCLUSION: Linezolid and daptomycin are potentially cost-effective based on the assumptions of the DA model; however, linezolid appears to be more cost-effective compared to daptomycin and vancomycin for MRSA cSSSIs.	Linezolid	119-128	solute carrier family 9 member A6	Homo sapiens	205-209
21839399-13	2011	CONCLUSION: Linezolid and daptomycin are potentially cost-effective based on the assumptions of the DA model; however, linezolid appears to be more cost-effective compared to daptomycin and vancomycin for MRSA cSSSIs.	Vancomycin	190-200	solute carrier family 9 member A6	Homo sapiens	205-209
21455712-0	2011	Glycopeptide and daptomycin resistance in community-associated MRSA in the UK.	Glycopeptides	0-12	solute carrier family 9 member A6	Homo sapiens	63-67
21455712-0	2011	Glycopeptide and daptomycin resistance in community-associated MRSA in the UK.	Daptomycin	17-27	solute carrier family 9 member A6	Homo sapiens	63-67
22204200-1	2011	OBJECTIVE: To evaluate the trend of mupirocin resistance in MRSA, isolated at the Clinical Microbiology Laboratory of a tertiary care hospital.	Mupirocin	36-45	solute carrier family 9 member A6	Homo sapiens	60-64
22204200-3	2011	RESULTS: High level and low level mupirocin resistance were detected in zero and 1% of MRSA strains, respectively.	Mupirocin	34-43	solute carrier family 9 member A6	Homo sapiens	87-91
22204200-6	2011	CONCLUSION: Mupirocin resistance was found to be very low among local clinical isolates of MRSA.	Mupirocin	12-21	solute carrier family 9 member A6	Homo sapiens	91-95
21229280-0	2011	Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem?	Vancomycin	0-10	solute carrier family 9 member A6	Homo sapiens	24-28
21229280-1	2011	The aim of this study was to assess the vancomycin MIC distribution for MRSA blood culture isolates over a period of six years in Germany.	Vancomycin	40-50	solute carrier family 9 member A6	Homo sapiens	72-76
21229280-4	2011	Genotypic features of the MRSA strains with vancomycin MIC >= 1 mg/L were determined by semiautomated repetitive-sequence-based polymerase chain reaction.	Vancomycin	44-54	solute carrier family 9 member A6	Homo sapiens	26-30
21229280-10	2011	We suggest that all hospitals should monitor their local status of elevated vancomycin MICs in invasive MRSA isolates.	Vancomycin	76-86	solute carrier family 9 member A6	Homo sapiens	104-108
21211014-1	2011	BACKGROUND: Staphylococcus aureus including methicillin resistant S. aureus, MRSA, are human colonizing bacteria that commonly cause opportunistic infections primarily involving the skin in otherwise healthy individuals.	Methicillin	44-55	solute carrier family 9 member A6	Homo sapiens	77-81
21132518-0	2011	Bio-inspired porous SiC ceramics loaded with vancomycin for preventing MRSA infections.	Vancomycin	45-55	solute carrier family 9 member A6	Homo sapiens	71-75
21211014-7	2011	Twelve of 15 MRSA isolates collected from the water had identical genetic characteristics as the organisms isolated from the participants exposed to that water while the remaining 3 MRSA were without matching nasal isolates from participants.	Water	46-51	solute carrier family 9 member A6	Homo sapiens	13-17
21211014-7	2011	Twelve of 15 MRSA isolates collected from the water had identical genetic characteristics as the organisms isolated from the participants exposed to that water while the remaining 3 MRSA were without matching nasal isolates from participants.	Water	154-159	solute carrier family 9 member A6	Homo sapiens	13-17
21144988-3	2011	Their use in the intensive care unit as empiric therapy is becoming compromised due to the development of multiple drug resistant gram negative pathogens and collateral damage with C difficile & MRSA.	difficile	183-192	solute carrier family 9 member A6	Homo sapiens	199-203
21144988-3	2011	Their use in the intensive care unit as empiric therapy is becoming compromised due to the development of multiple drug resistant gram negative pathogens and collateral damage with C difficile & MRSA.	Adenosine Monophosphate	194-197	solute carrier family 9 member A6	Homo sapiens	199-203
22830148-12	2011	Linezolid was used for MRSA.	Linezolid	0-9	solute carrier family 9 member A6	Homo sapiens	23-27
22830148-19	2011	MRSA was treated successfully with Linezolid.	Linezolid	35-44	solute carrier family 9 member A6	Homo sapiens	0-4
20483504-0	2010	Oxacillin-susceptible MRSA, the emerging MRSA clone in the UK?	Oxacillin	0-9	solute carrier family 9 member A6	Homo sapiens	22-26
20949524-2	2010	Gilfillan et al.2008] reported mutations in SLC9A6, the gene encoding the sodium/hydrogen exchanger NHE6, in the family first reported and in three others.	Sodium	74-80	solute carrier family 9 member A6	Homo sapiens	44-50
20949524-2	2010	Gilfillan et al.2008] reported mutations in SLC9A6, the gene encoding the sodium/hydrogen exchanger NHE6, in the family first reported and in three others.	Sodium	74-80	solute carrier family 9 member A6	Homo sapiens	100-104
20949524-2	2010	Gilfillan et al.2008] reported mutations in SLC9A6, the gene encoding the sodium/hydrogen exchanger NHE6, in the family first reported and in three others.	Hydrogen	81-89	solute carrier family 9 member A6	Homo sapiens	44-50
20949524-2	2010	Gilfillan et al.2008] reported mutations in SLC9A6, the gene encoding the sodium/hydrogen exchanger NHE6, in the family first reported and in three others.	Hydrogen	81-89	solute carrier family 9 member A6	Homo sapiens	100-104
20483504-0	2010	Oxacillin-susceptible MRSA, the emerging MRSA clone in the UK?	Oxacillin	0-9	solute carrier family 9 member A6	Homo sapiens	41-45
20429820-11	2010	The finding of lower vancomycin efficacy in MRSA cSSTI did not change in sensitivity analyses.	Vancomycin	21-31	solute carrier family 9 member A6	Homo sapiens	44-48
20429820-12	2010	CONCLUSION: The results of this meta-analysis suggest higher success rates for linezolid and the new glycopeptides (dalbavancin and telavancin) in MRSA-confirmed cSSTIs.	Linezolid	79-88	solute carrier family 9 member A6	Homo sapiens	147-151
20429820-12	2010	CONCLUSION: The results of this meta-analysis suggest higher success rates for linezolid and the new glycopeptides (dalbavancin and telavancin) in MRSA-confirmed cSSTIs.	Glycopeptides	101-114	solute carrier family 9 member A6	Homo sapiens	147-151
20429820-12	2010	CONCLUSION: The results of this meta-analysis suggest higher success rates for linezolid and the new glycopeptides (dalbavancin and telavancin) in MRSA-confirmed cSSTIs.	dalbavancin	116-127	solute carrier family 9 member A6	Homo sapiens	147-151
20429820-12	2010	CONCLUSION: The results of this meta-analysis suggest higher success rates for linezolid and the new glycopeptides (dalbavancin and telavancin) in MRSA-confirmed cSSTIs.	telavancin	132-142	solute carrier family 9 member A6	Homo sapiens	147-151
22338440-17	2010	except MRSA where Linezolid, vancomycin and Tiecoplanin were effective.	tiecoplanin	44-55	solute carrier family 9 member A6	Homo sapiens	7-11
20001574-0	2010	Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.	Linezolid	23-32	solute carrier family 9 member A6	Homo sapiens	81-85
20381913-0	2010	Mupirocin-resistant MRSA transmission associated with community hospitals and nursing homes.	Mupirocin	0-9	solute carrier family 9 member A6	Homo sapiens	20-24
20364249-9	2010	However, NHE6 with alanine substitutions in the membrane-proximal region exhibited no apparent change in localization.	Alanine	19-26	solute carrier family 9 member A6	Homo sapiens	9-13
20001574-1	2010	OBJECTIVE: To evaluate the clinical and microbiological outcomes of linezolid versus vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infection (cSSTI) using a meta-analysis.	Vancomycin	85-95	solute carrier family 9 member A6	Homo sapiens	144-148
20001574-10	2010	Microbiological eradication in MRSA ME patients consistently favored the use of linezolid over vancomycin (OR = 2.90; 95% CI: 1.90, 4.41).	Linezolid	80-89	solute carrier family 9 member A6	Homo sapiens	31-35
20001574-10	2010	Microbiological eradication in MRSA ME patients consistently favored the use of linezolid over vancomycin (OR = 2.90; 95% CI: 1.90, 4.41).	Vancomycin	95-105	solute carrier family 9 member A6	Homo sapiens	31-35
20001574-15	2010	CONCLUSION: Resolution of infection in CE and MITT patients were inconsistent; however, a sub-analysis revealed that linezolid was more likely to consistently achieve microbiologic eradication in MRSA ME patients.	Linezolid	117-126	solute carrier family 9 member A6	Homo sapiens	196-200
20001574-16	2010	Apparent risks of thrombocytopenia, nausea, diarrhea, and possibly anemia may limit linezolid use in treating MRSA cSSTI.	Linezolid	84-93	solute carrier family 9 member A6	Homo sapiens	110-120
19364845-1	2009	Limited treatment options are available for implant-associated infections caused by methicillin (meticillin)-resistant Staphylococcus aureus (MRSA).	Methicillin	84-95	solute carrier family 9 member A6	Homo sapiens	142-146
19846648-1	2009	The clinical utility of real-time PCR screening assays for methicillin (methicillin)-resistant Staphylococcus aureus (MRSA) colonization is constrained by the predictive values of their results: as MRSA prevalence falls, the assay"s positive predictive value (PPV) drops, and a rising proportion of positive PCR assays will not be confirmed by culture.	Methicillin	59-70	solute carrier family 9 member A6	Homo sapiens	118-122
19846648-1	2009	The clinical utility of real-time PCR screening assays for methicillin (methicillin)-resistant Staphylococcus aureus (MRSA) colonization is constrained by the predictive values of their results: as MRSA prevalence falls, the assay"s positive predictive value (PPV) drops, and a rising proportion of positive PCR assays will not be confirmed by culture.	Methicillin	59-70	solute carrier family 9 member A6	Homo sapiens	198-202
19846648-1	2009	The clinical utility of real-time PCR screening assays for methicillin (methicillin)-resistant Staphylococcus aureus (MRSA) colonization is constrained by the predictive values of their results: as MRSA prevalence falls, the assay"s positive predictive value (PPV) drops, and a rising proportion of positive PCR assays will not be confirmed by culture.	Methicillin	72-83	solute carrier family 9 member A6	Homo sapiens	118-122
19846648-1	2009	The clinical utility of real-time PCR screening assays for methicillin (methicillin)-resistant Staphylococcus aureus (MRSA) colonization is constrained by the predictive values of their results: as MRSA prevalence falls, the assay"s positive predictive value (PPV) drops, and a rising proportion of positive PCR assays will not be confirmed by culture.	Methicillin	72-83	solute carrier family 9 member A6	Homo sapiens	198-202
20090137-1	2009	BACKGROUND & OBJECTIVE: Community acquired methicillin resistant Staphylococcus aureus (CA-MRSA) is a major global problem.	Adenosine Monophosphate	12-15	solute carrier family 9 member A6	Homo sapiens	95-99
19364845-1	2009	Limited treatment options are available for implant-associated infections caused by methicillin (meticillin)-resistant Staphylococcus aureus (MRSA).	Methicillin	97-107	solute carrier family 9 member A6	Homo sapiens	142-146
19364845-3	2009	The daptomycin MIC and the minimum bactericidal concentration in logarithmic phase and stationary growth phase of MRSA were 0.625, 0.625, and 20 microg/ml, respectively.	Daptomycin	4-14	solute carrier family 9 member A6	Homo sapiens	114-118
19364845-4	2009	In time-kill studies, daptomycin showed rapid and concentration-dependent killing of MRSA in stationary growth phase.	Daptomycin	22-32	solute carrier family 9 member A6	Homo sapiens	85-89
19364845-6	2009	In treatment studies, daptomycin alone reduced the planktonic MRSA counts by 0.3 log(10) CFU/ml, whereas in combination with rifampin, a reduction in the counts of >6 log(10) CFU/ml was observed.	Daptomycin	22-32	solute carrier family 9 member A6	Homo sapiens	62-66
19364845-9	2009	In addition, daptomycin at a high dose (30 mg/kg) completely prevented the emergence of rifampin resistance in planktonic and adherent MRSA cells.	Daptomycin	13-23	solute carrier family 9 member A6	Homo sapiens	135-139
19364845-9	2009	In addition, daptomycin at a high dose (30 mg/kg) completely prevented the emergence of rifampin resistance in planktonic and adherent MRSA cells.	Rifampin	88-96	solute carrier family 9 member A6	Homo sapiens	135-139
19364845-10	2009	Daptomycin at a high dose, corresponding to 6 mg/kg in humans, in combination with rifampin showed the highest activity against planktonic and adherent MRSA.	Daptomycin	0-10	solute carrier family 9 member A6	Homo sapiens	152-156
19364845-10	2009	Daptomycin at a high dose, corresponding to 6 mg/kg in humans, in combination with rifampin showed the highest activity against planktonic and adherent MRSA.	Rifampin	83-91	solute carrier family 9 member A6	Homo sapiens	152-156
19364845-11	2009	Daptomycin plus rifampin is a promising treatment option for implant-associated MRSA infections.	Daptomycin	0-10	solute carrier family 9 member A6	Homo sapiens	80-84
19364845-11	2009	Daptomycin plus rifampin is a promising treatment option for implant-associated MRSA infections.	Rifampin	16-24	solute carrier family 9 member A6	Homo sapiens	80-84
19489364-8	2009	Our CA-MRSA isolates were 98.6% sensitive to trimethoprim-sulfamethoxasole, 94.4% sensitive to tetracycline, 90.8% sensitive to clindamycin, and 59.9% sensitive to levofloxacin.	trimethoprim-sulfamethoxasole	45-74	solute carrier family 9 member A6	Homo sapiens	7-11
19344266-4	2009	PATIENTS: A cohort of 182 consecutive patients who developed nosocomial BSI due to methicillin-susceptible and methicillin-resistant S. aureus (MSSA and MRSA, respectively) RESULTS: Patients with MRSA BSI had a significantly longer total length of hospital and intensive care unit (ICU) stay before the onset of BSI and a higher average daily cost.	Methicillin	83-94	solute carrier family 9 member A6	Homo sapiens	196-200
19344266-4	2009	PATIENTS: A cohort of 182 consecutive patients who developed nosocomial BSI due to methicillin-susceptible and methicillin-resistant S. aureus (MSSA and MRSA, respectively) RESULTS: Patients with MRSA BSI had a significantly longer total length of hospital and intensive care unit (ICU) stay before the onset of BSI and a higher average daily cost.	Methicillin	111-122	solute carrier family 9 member A6	Homo sapiens	196-200
19417720-0	2009	Drugs for MRSA with reduced susceptibility to vancomycin.	Vancomycin	46-56	solute carrier family 9 member A6	Homo sapiens	10-14
19489364-8	2009	Our CA-MRSA isolates were 98.6% sensitive to trimethoprim-sulfamethoxasole, 94.4% sensitive to tetracycline, 90.8% sensitive to clindamycin, and 59.9% sensitive to levofloxacin.	Tetracycline	95-107	solute carrier family 9 member A6	Homo sapiens	7-11
19489364-8	2009	Our CA-MRSA isolates were 98.6% sensitive to trimethoprim-sulfamethoxasole, 94.4% sensitive to tetracycline, 90.8% sensitive to clindamycin, and 59.9% sensitive to levofloxacin.	Clindamycin	128-139	solute carrier family 9 member A6	Homo sapiens	7-11
19489364-8	2009	Our CA-MRSA isolates were 98.6% sensitive to trimethoprim-sulfamethoxasole, 94.4% sensitive to tetracycline, 90.8% sensitive to clindamycin, and 59.9% sensitive to levofloxacin.	Levofloxacin	164-176	solute carrier family 9 member A6	Homo sapiens	7-11
19053903-2	2008	The CA-MRSA strains are more likely to carry the genes for the Panton-Valentine leukocidin toxin and have increased susceptibility to non-beta-lactam antibiotics.	beta-Lactams	138-149	solute carrier family 9 member A6	Homo sapiens	7-11
21794562-1	2008	One of the soft-tissue infections with a large clinical relevance is necrotizing fascitis produced by Streptococcus pyogenes and skin infections produced by Staphylococcus aureus, particularly due to the evermore frequent methylcillin (MRSA) resistant varieties.	methylcillin	222-234	solute carrier family 9 member A6	Homo sapiens	236-240
18544597-0	2008	Susceptibility of 170 isolates of the USA300 clone of MRSA to macrolides, clindamycin and the novel ketolide cethromycin.	Macrolides	62-72	solute carrier family 9 member A6	Homo sapiens	54-58
18544597-0	2008	Susceptibility of 170 isolates of the USA300 clone of MRSA to macrolides, clindamycin and the novel ketolide cethromycin.	Clindamycin	74-85	solute carrier family 9 member A6	Homo sapiens	54-58
18544597-0	2008	Susceptibility of 170 isolates of the USA300 clone of MRSA to macrolides, clindamycin and the novel ketolide cethromycin.	Ketolides	100-108	solute carrier family 9 member A6	Homo sapiens	54-58
18544597-0	2008	Susceptibility of 170 isolates of the USA300 clone of MRSA to macrolides, clindamycin and the novel ketolide cethromycin.	cethromycin	109-120	solute carrier family 9 member A6	Homo sapiens	54-58
18372271-0	2008	A case report of the use of nanocrystalline silver dressing in the management of acute surgical site wound infected with MRSA to prevent cutaneous necrosis following revision surgery.	nanocrystalline	28-43	solute carrier family 9 member A6	Homo sapiens	121-125
18585915-6	2008	Here, we discuss the roles of PVL, the arginine catabolic mobile element and phenol-soluble modulins in the pathogenesis of prevalent CA-MRSA strains.	Phenol	77-83	solute carrier family 9 member A6	Homo sapiens	137-141
18722220-8	2008	All of the CA-MRSA strains identified in our study were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX).	Trimethoprim, Sulfamethoxazole Drug Combination	71-100	solute carrier family 9 member A6	Homo sapiens	14-18
18722220-8	2008	All of the CA-MRSA strains identified in our study were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX).	Trimethoprim, Sulfamethoxazole Drug Combination	102-109	solute carrier family 9 member A6	Homo sapiens	14-18
17513023-2	2007	About 40% of the strains are resistant to methicillin (MRSA).	Methicillin	42-53	solute carrier family 9 member A6	Homo sapiens	55-59
17852899-0	2008	Long-term use of daptomycin for MRSA osteomyelitis and joint infection.	Daptomycin	17-27	solute carrier family 9 member A6	Homo sapiens	32-36
21694913-4	2008	We present a case of a hemodialysis patient who developed osteomyelitis of the entire right hemipelvis due to MRSA bacteremia after repeated attempts at TCC salvage.	Triclocarban	153-156	solute carrier family 9 member A6	Homo sapiens	110-114
17513023-6	2007	At the same time, intermediate sensitive and resistant MRSA strains to glycopeptides appeared.	Glycopeptides	71-84	solute carrier family 9 member A6	Homo sapiens	55-59
17439976-0	2007	Low-level exposure of MRSA to octenidine dihydrochloride does not select for resistance.	octenidine	30-56	solute carrier family 9 member A6	Homo sapiens	22-26
17933423-10	2007	Ciprofloxacin-containing media should be used with caution for MRSA screening in settings where ciprofloxacin-susceptible strains (including community-associated MRSA) are increasing in prevalence.	Ciprofloxacin	0-13	solute carrier family 9 member A6	Homo sapiens	63-67
17933423-10	2007	Ciprofloxacin-containing media should be used with caution for MRSA screening in settings where ciprofloxacin-susceptible strains (including community-associated MRSA) are increasing in prevalence.	Ciprofloxacin	0-13	solute carrier family 9 member A6	Homo sapiens	162-166
17563032-0	2007	Is high minimal inhibitory concentration of vancomycin a predictor of poor response in MRSA infections?	vancomycin a	44-56	solute carrier family 9 member A6	Homo sapiens	87-91
17646910-3	2007	We wanted to assess the effectiveness of MRSA eradication procedures--especially octenidine whole body washings and mupirocin nasal ointment--under conditions of everyday life.	octenidine	81-91	solute carrier family 9 member A6	Homo sapiens	41-45
17588430-5	2007	The patient had MRSA sepsis develop resistant to conventional therapy, which was successfully treated with daptomycin.	Daptomycin	107-117	solute carrier family 9 member A6	Homo sapiens	16-20
17020429-0	2006	Cephalosporins for uncomplicated skin and skin structure infections in emerging community-acquired MRSA.	Cephalosporins	0-14	solute carrier family 9 member A6	Homo sapiens	99-103
17157008-4	2007	Some of them exhibited superior antibacterial activity against quinolone-susceptible MRSA in comparison with clinically used fluoroquinolones, such as levofloxacin, ciprofloxacin, and gatifloxacin.	Quinolones	63-72	solute carrier family 9 member A6	Homo sapiens	85-89
16716610-6	2006	A simple decision analysis model suggests that gentamicin should be used when the prevalence of MRSA reaches 10% and vancomycin when the prevalence reaches 50%.	Gentamicins	47-57	solute carrier family 9 member A6	Homo sapiens	96-100
17198732-11	2007	However, 11/14 (79%) MRSA patients who received rifampin combinations, other than vancomycin and rifampin simultaneously, were apparently cured.	Rifampin	48-56	solute carrier family 9 member A6	Homo sapiens	21-25
17020429-4	2006	In addition, the use of antimicrobial agents in infective strains that may be resistant does not appear to be associated with adverse patient-reported outcomes, suggesting that cephalosporins may still be effective in treating community-acquired MRSA-associated SSSIs.	Cephalosporins	177-191	solute carrier family 9 member A6	Homo sapiens	246-250
16983899-4	2006	The presence of an atypical skin infection in patients with AD, particularly those unresponsive to conventional penicillinase-resistant penicillins and cephalosporins, should alert the clinician to the possibility of MRSA as the underlying etiology, and intervention should be directed accordingly.	Cephalosporins	152-166	solute carrier family 9 member A6	Homo sapiens	217-221
17185859-0	2006	Beta-lactam antibiotic susceptibility testing of MRSA?	beta-Lactams	0-11	solute carrier family 9 member A6	Homo sapiens	49-53
16903411-0	2006	Topical manuka honey for MRSA-contaminated skin ulcers.	manuka honey	8-20	solute carrier family 9 member A6	Homo sapiens	25-29
16178292-1	2005	Patients were being transferred from nursing homes to hospital with MRSA in their PEG sites.	Polyethylene Glycols	82-85	solute carrier family 9 member A6	Homo sapiens	68-72
16570547-3	2006	The choice of vancomycin over a cephalosporin may be justified in patients who are known carriers of MRSA.	Vancomycin	14-24	solute carrier family 9 member A6	Homo sapiens	101-105
16570547-3	2006	The choice of vancomycin over a cephalosporin may be justified in patients who are known carriers of MRSA.	Cephalosporins	32-45	solute carrier family 9 member A6	Homo sapiens	101-105
17340994-0	2006	[MIC and MBC of quinupristin/dalfopristin of erythromycin-resistant MRSA strains isolated from clinical specimens].	quinupristin	16-28	solute carrier family 9 member A6	Homo sapiens	68-72
17340994-0	2006	[MIC and MBC of quinupristin/dalfopristin of erythromycin-resistant MRSA strains isolated from clinical specimens].	dalfopristin	29-41	solute carrier family 9 member A6	Homo sapiens	68-72
17340994-0	2006	[MIC and MBC of quinupristin/dalfopristin of erythromycin-resistant MRSA strains isolated from clinical specimens].	Erythromycin	45-57	solute carrier family 9 member A6	Homo sapiens	68-72
17340994-1	2006	The MICs and MBCs of quinupristin/dalfopristin were determined for 22 clinical strains MRSA with inducible type of resistance to MLS-B and for 15 of their derivatives with constitutive resistance to MLS-B.	quinupristin	21-33	solute carrier family 9 member A6	Homo sapiens	87-91
17340994-2	2006	For MRSA strains with inducible resistance to MLS-B the obtained results for quinupristin/ dalfopristin were: MIC50 = 0.25, MIC90 = 0.5, MBC50 = 1.0 and MBC90 = 1.0.	quinupristin	77-89	solute carrier family 9 member A6	Homo sapiens	4-8
17340994-2	2006	For MRSA strains with inducible resistance to MLS-B the obtained results for quinupristin/ dalfopristin were: MIC50 = 0.25, MIC90 = 0.5, MBC50 = 1.0 and MBC90 = 1.0.	dalfopristin	91-103	solute carrier family 9 member A6	Homo sapiens	4-8
17571573-7	2006	Teicoplanin was active against against all MRSA excepted one of the strain, with an reduced susceptibility.	Teicoplanin	0-11	solute carrier family 9 member A6	Homo sapiens	43-47
16547394-6	2006	In conclusion, the Maeda"s nomogram regimen with a 1,000 mg vancomycin dose was shown to achieve target plasma levels of vancomycin at a higher rate and provide higher clinical efficacy in vancomycin therapy of MRSA pneumonia patients, as compared with the currently available standard dosage regimen.	Vancomycin	60-70	solute carrier family 9 member A6	Homo sapiens	211-215
16547394-6	2006	In conclusion, the Maeda"s nomogram regimen with a 1,000 mg vancomycin dose was shown to achieve target plasma levels of vancomycin at a higher rate and provide higher clinical efficacy in vancomycin therapy of MRSA pneumonia patients, as compared with the currently available standard dosage regimen.	Vancomycin	121-131	solute carrier family 9 member A6	Homo sapiens	211-215
16547394-6	2006	In conclusion, the Maeda"s nomogram regimen with a 1,000 mg vancomycin dose was shown to achieve target plasma levels of vancomycin at a higher rate and provide higher clinical efficacy in vancomycin therapy of MRSA pneumonia patients, as compared with the currently available standard dosage regimen.	Vancomycin	121-131	solute carrier family 9 member A6	Homo sapiens	211-215
16424973-9	2006	These results suggest teicoplanin may be useful in patients undergoing orthopedic surgery when the prevalence of MRSA is high.	Teicoplanin	22-33	solute carrier family 9 member A6	Homo sapiens	113-117
17009779-0	2006	[Small change, large effect--a new vancomycin derivative against MRSA].	Vancomycin	35-45	solute carrier family 9 member A6	Homo sapiens	65-70
16341337-1	2005	Staphylococcus aureus is a major cause of infections in both hospitals and communities, and is exhibiting increasing resistance to methicillin (methicillin-resistant S. aureus, MRSA) and related beta-lactams.	Methicillin	131-142	solute carrier family 9 member A6	Homo sapiens	177-181
16341337-5	2005	Compared with those reported from the US and other countries, CA-MRSA isolates in Taiwan did not always harbor type IV staphylococcal cassette chromosome (SCCmec) and were resistant to multiple non-beta-lactam antibiotics, including clindamycin and macrolides.	beta-Lactams	198-209	solute carrier family 9 member A6	Homo sapiens	65-69
16341337-5	2005	Compared with those reported from the US and other countries, CA-MRSA isolates in Taiwan did not always harbor type IV staphylococcal cassette chromosome (SCCmec) and were resistant to multiple non-beta-lactam antibiotics, including clindamycin and macrolides.	Clindamycin	233-244	solute carrier family 9 member A6	Homo sapiens	65-69
16341337-5	2005	Compared with those reported from the US and other countries, CA-MRSA isolates in Taiwan did not always harbor type IV staphylococcal cassette chromosome (SCCmec) and were resistant to multiple non-beta-lactam antibiotics, including clindamycin and macrolides.	Macrolides	249-259	solute carrier family 9 member A6	Homo sapiens	65-69
16262432-1	2005	The thiopeptide (or thiostrepton) antibiotics are a class of sulfur containing highly modified cyclic peptides with interesting biological properties, including reported activity against MRSA and malaria.	Thiostrepton	20-32	solute carrier family 9 member A6	Homo sapiens	187-191
16262432-1	2005	The thiopeptide (or thiostrepton) antibiotics are a class of sulfur containing highly modified cyclic peptides with interesting biological properties, including reported activity against MRSA and malaria.	Sulfur	61-67	solute carrier family 9 member A6	Homo sapiens	187-191
16262432-1	2005	The thiopeptide (or thiostrepton) antibiotics are a class of sulfur containing highly modified cyclic peptides with interesting biological properties, including reported activity against MRSA and malaria.	Peptides, Cyclic	95-110	solute carrier family 9 member A6	Homo sapiens	187-191
16155048-1	2005	OBJECTIVE: To describe the incidence and determinants of methicillin resistant and methicillin sensitive Staphylococcus aureus (MRSA and MSSA) bacteraemia in patients presenting to acute hospitals.	Methicillin	57-68	solute carrier family 9 member A6	Homo sapiens	128-132
16155048-1	2005	OBJECTIVE: To describe the incidence and determinants of methicillin resistant and methicillin sensitive Staphylococcus aureus (MRSA and MSSA) bacteraemia in patients presenting to acute hospitals.	Methicillin	83-94	solute carrier family 9 member A6	Homo sapiens	128-132
15681583-0	2005	In vivo synergy of daptomycin plus a penicillin agent for MRSA?	Daptomycin	19-29	solute carrier family 9 member A6	Homo sapiens	58-62
15986222-2	2005	Treatment options for infections with MRSA are extremely limited because of resistance to all beta-lactam antibiotics and primarily because of the fast acquisition of further antibiotic resistance.	beta-Lactams	94-105	solute carrier family 9 member A6	Homo sapiens	38-42
15834098-6	2005	CONCLUSION: Moxifloxacin penetrates well into the anterior chamber of the human uninflamed eye after oral administration, reaching early significant levels, which are maintained for at least 12 hours and are much higher than the MIC(90) values of Gram positive and Gram negative pathogens commonly implicated in intraocular infections with the exceptions of fluoroquinolone resistant staphylococci, MRSA, and Pseudomonas aeruginosa.	Moxifloxacin	12-24	solute carrier family 9 member A6	Homo sapiens	399-403
16094598-0	2005	Efficacy of vancomycin-impregnated cement beads for the treatment of MRSA infection of failed graft tissue at the mandible.	Vancomycin	12-22	solute carrier family 9 member A6	Homo sapiens	69-73
15922531-1	2005	OBJECTIVE: The methicillin resistance of Staphylococcus aureus MRSA is a major problem for human infections.	Methicillin	15-26	solute carrier family 9 member A6	Homo sapiens	63-67
15681583-0	2005	In vivo synergy of daptomycin plus a penicillin agent for MRSA?	Penicillins	37-47	solute carrier family 9 member A6	Homo sapiens	58-62
15320440-1	2004	DISTURBING EPIDEMIOLOGICAL DATA: Over the past decade there has been a continuous progression in the percentage of Staphylococcus aureus strains resistant to methicillin (MRSA), a slight progression in coagulase-negative staphylococci strains resistant to methicillin and a spectacular progression of enterococci resistant to glycopeptides, not only in hospitals but also in intensive care settings.	Methicillin	158-169	solute carrier family 9 member A6	Homo sapiens	171-175
16400877-9	2005	The 1100 MRSA isolates distributed to four antibiotic resistance patterns on the basis of their resistance to oxacillin, penicillin, amoxicillin+clavulanic acid, azithromycin, clindamycin, amikacin, gentamicin, ciprofloxacin, trimethoprim+sulphamethoxasole, vancomycin and teicoplanin.	Oxacillin	110-119	solute carrier family 9 member A6	Homo sapiens	9-13
16400877-9	2005	The 1100 MRSA isolates distributed to four antibiotic resistance patterns on the basis of their resistance to oxacillin, penicillin, amoxicillin+clavulanic acid, azithromycin, clindamycin, amikacin, gentamicin, ciprofloxacin, trimethoprim+sulphamethoxasole, vancomycin and teicoplanin.	Penicillins	121-131	solute carrier family 9 member A6	Homo sapiens	9-13
16400877-9	2005	The 1100 MRSA isolates distributed to four antibiotic resistance patterns on the basis of their resistance to oxacillin, penicillin, amoxicillin+clavulanic acid, azithromycin, clindamycin, amikacin, gentamicin, ciprofloxacin, trimethoprim+sulphamethoxasole, vancomycin and teicoplanin.	Amoxicillin-Potassium Clavulanate Combination	133-160	solute carrier family 9 member A6	Homo sapiens	9-13
16400877-9	2005	The 1100 MRSA isolates distributed to four antibiotic resistance patterns on the basis of their resistance to oxacillin, penicillin, amoxicillin+clavulanic acid, azithromycin, clindamycin, amikacin, gentamicin, ciprofloxacin, trimethoprim+sulphamethoxasole, vancomycin and teicoplanin.	Azithromycin	162-174	solute carrier family 9 member A6	Homo sapiens	9-13
16400877-9	2005	The 1100 MRSA isolates distributed to four antibiotic resistance patterns on the basis of their resistance to oxacillin, penicillin, amoxicillin+clavulanic acid, azithromycin, clindamycin, amikacin, gentamicin, ciprofloxacin, trimethoprim+sulphamethoxasole, vancomycin and teicoplanin.	Amikacin	189-197	solute carrier family 9 member A6	Homo sapiens	9-13
16400877-9	2005	The 1100 MRSA isolates distributed to four antibiotic resistance patterns on the basis of their resistance to oxacillin, penicillin, amoxicillin+clavulanic acid, azithromycin, clindamycin, amikacin, gentamicin, ciprofloxacin, trimethoprim+sulphamethoxasole, vancomycin and teicoplanin.	Gentamicins	199-209	solute carrier family 9 member A6	Homo sapiens	9-13
16400877-9	2005	The 1100 MRSA isolates distributed to four antibiotic resistance patterns on the basis of their resistance to oxacillin, penicillin, amoxicillin+clavulanic acid, azithromycin, clindamycin, amikacin, gentamicin, ciprofloxacin, trimethoprim+sulphamethoxasole, vancomycin and teicoplanin.	Ciprofloxacin	211-224	solute carrier family 9 member A6	Homo sapiens	9-13
16400877-9	2005	The 1100 MRSA isolates distributed to four antibiotic resistance patterns on the basis of their resistance to oxacillin, penicillin, amoxicillin+clavulanic acid, azithromycin, clindamycin, amikacin, gentamicin, ciprofloxacin, trimethoprim+sulphamethoxasole, vancomycin and teicoplanin.	trimethoprim+sulphamethoxasole	226-256	solute carrier family 9 member A6	Homo sapiens	9-13
16400877-9	2005	The 1100 MRSA isolates distributed to four antibiotic resistance patterns on the basis of their resistance to oxacillin, penicillin, amoxicillin+clavulanic acid, azithromycin, clindamycin, amikacin, gentamicin, ciprofloxacin, trimethoprim+sulphamethoxasole, vancomycin and teicoplanin.	Vancomycin	258-268	solute carrier family 9 member A6	Homo sapiens	9-13
16400877-9	2005	The 1100 MRSA isolates distributed to four antibiotic resistance patterns on the basis of their resistance to oxacillin, penicillin, amoxicillin+clavulanic acid, azithromycin, clindamycin, amikacin, gentamicin, ciprofloxacin, trimethoprim+sulphamethoxasole, vancomycin and teicoplanin.	Teicoplanin	273-284	solute carrier family 9 member A6	Homo sapiens	9-13
16400877-10	2005	All the MRSA isolates were multidrug resistant but sensitive to glycopeptides.	Glycopeptides	64-77	solute carrier family 9 member A6	Homo sapiens	8-12
15465268-0	2004	[Increased susceptibility to non-beta-lactam antimicrobial agents of MRSA isolates: relationship between genotype and antibiotype].	beta-Lactams	33-44	solute carrier family 9 member A6	Homo sapiens	69-73
15465268-5	2004	In contrast, the proportion of MRSA susceptible to erythromycin progressively increased from 7.0% to 32.5% (P < 0.001).	Erythromycin	51-63	solute carrier family 9 member A6	Homo sapiens	31-35
15465268-10	2004	The increase of erythromycin-susceptibility within MRSA was caused by the emergence of clone C. Non-epidemic strains were more frequently susceptible to ofloxacin (31.8% vs. 1.1%) and tobramycin (45.4% vs. 16.8%) than epidemic strains.	Erythromycin	16-28	solute carrier family 9 member A6	Homo sapiens	51-55
15350720-0	2004	The value of using chlorhexidine soap in a controlled trial to eradicate MRSA in colonized patients.	Chlorhexidine	19-32	solute carrier family 9 member A6	Homo sapiens	73-77
15320440-1	2004	DISTURBING EPIDEMIOLOGICAL DATA: Over the past decade there has been a continuous progression in the percentage of Staphylococcus aureus strains resistant to methicillin (MRSA), a slight progression in coagulase-negative staphylococci strains resistant to methicillin and a spectacular progression of enterococci resistant to glycopeptides, not only in hospitals but also in intensive care settings.	Methicillin	256-267	solute carrier family 9 member A6	Homo sapiens	171-175
15320440-1	2004	DISTURBING EPIDEMIOLOGICAL DATA: Over the past decade there has been a continuous progression in the percentage of Staphylococcus aureus strains resistant to methicillin (MRSA), a slight progression in coagulase-negative staphylococci strains resistant to methicillin and a spectacular progression of enterococci resistant to glycopeptides, not only in hospitals but also in intensive care settings.	Glycopeptides	326-339	solute carrier family 9 member A6	Homo sapiens	171-175
15320441-2	2004	THE IMPACT OF MRSA INFECTIONS: Is clinical to start, with a greater mortality rate in MRSA bacteremias than in staphylococcal sensitive, in vancomycin-resistant enterococcal infections than in enterococcal sensitive infections, and in acquired pneumonia under mechanical ventilation.	Vancomycin	140-150	solute carrier family 9 member A6	Homo sapiens	14-18
15175106-12	2004	CONCLUSIONS: Progressive eradication of MRSA carriage was observed with the antiseptic soap and mupirocin.	Mupirocin	96-105	solute carrier family 9 member A6	Homo sapiens	40-44
15311566-4	2004	There has been an alarming rise in the incidence of MRSA, which has jumped from a reported 2% in 1992 to about 42% in 2001 in England & Wales.	Adenosine Monophosphate	135-138	solute carrier family 9 member A6	Homo sapiens	52-56
15311566-5	2004	Use of antibiotic may lead to emergence of MRSA in debilitated patients requiring PEG feeding.	Polyethylene Glycols	82-85	solute carrier family 9 member A6	Homo sapiens	43-47
14767588-0	2004	Linezolid in VAP by MRSA: a better choice?	Linezolid	0-9	solute carrier family 9 member A6	Homo sapiens	20-24
17642608-0	2004	Silver sulphadiazine for MRSA infections.	Silver Sulfadiazine	0-20	solute carrier family 9 member A6	Homo sapiens	25-29
14574840-2	2003	In order to apply chemiluminescent assay to detection of MRSA, we compared MIC and antimicrobial susceptibility to MPIPC in using chemiluminescent assay with these in using broth microdilution method.	mpipc	115-120	solute carrier family 9 member A6	Homo sapiens	57-61
15449791-14	2003	For those infections acquired in the hospital therapy with third or fourth generation cephalosporins, carbapenems, beta-lactams with betalactamase inhibitors alone or in combination with an aminoglucoside and or vancomycin if MRSA is suspected is accepted therapy.	Cephalosporins	86-100	solute carrier family 9 member A6	Homo sapiens	226-230
15449791-14	2003	For those infections acquired in the hospital therapy with third or fourth generation cephalosporins, carbapenems, beta-lactams with betalactamase inhibitors alone or in combination with an aminoglucoside and or vancomycin if MRSA is suspected is accepted therapy.	beta-Lactams	115-127	solute carrier family 9 member A6	Homo sapiens	226-230
15449791-14	2003	For those infections acquired in the hospital therapy with third or fourth generation cephalosporins, carbapenems, beta-lactams with betalactamase inhibitors alone or in combination with an aminoglucoside and or vancomycin if MRSA is suspected is accepted therapy.	Vancomycin	212-222	solute carrier family 9 member A6	Homo sapiens	226-230
14572485-4	2003	There were five patients from whom methicillin-sensitive S. aureus (MRSA) could be detected in oral specimens.	Methicillin	35-46	solute carrier family 9 member A6	Homo sapiens	68-72
14572485-7	2003	There were five patients from whom methicillin-sensitive S. aureus (MRSA) could be detected in the oral specimens.	Methicillin	35-46	solute carrier family 9 member A6	Homo sapiens	68-72
14510247-11	2003	CONCLUSION: Through multivariate modeling techniques, we were able to identify the most important determinants of MRSA at our institution and develop a tool to predict the probability of methicillin resistance in a patient with SAB.	sab	228-231	solute carrier family 9 member A6	Homo sapiens	114-118
14564255-4	2003	Following the dehiscence of the thoracotomy surgical wound, a severe infective clinical picture, sustained by methicillin-resistant S. Aureus (MRSA), became evident with a diagnosis of bacterial endocarditis involving the aortic, mitral and tricuspid valves and caused the patient"s death due to septic shock complicated by ARDS.	Methicillin	110-121	solute carrier family 9 member A6	Homo sapiens	143-147
12594655-0	2003	Persistent MRSA bacteremia in a patient with low linezolid levels.	Linezolid	49-58	solute carrier family 9 member A6	Homo sapiens	11-15
12617235-7	2002	Gentamicin is active against more than 95% of MRSA strains cultured in our hospital and against 87% of MRSA strains cultured in the neurosurgery unit.	Gentamicins	0-10	solute carrier family 9 member A6	Homo sapiens	46-50
12623326-1	2003	We investigated the effects of inhalation of tea catechin on MRSA in the 24 elderly in patients, who were known to carry MRSA in sputum.	Catechin	49-57	solute carrier family 9 member A6	Homo sapiens	61-65
12623326-4	2003	After a week of the course, the numbers of the patients with decreased or disappearance of MRSA in their sputum was significantly higher in the catechin group, compared with that in the control group (seven vs. no patients; P<0.05).	Catechin	144-152	solute carrier family 9 member A6	Homo sapiens	91-95
12623326-8	2003	Catechin inhalation seemed to be safe, and at least temporarily effective in the reduction of MRSA and shortening of hospitalization.	Catechin	0-8	solute carrier family 9 member A6	Homo sapiens	94-98
12493811-0	2003	Susceptibility of MRSA to triclosan.	Triclosan	26-35	solute carrier family 9 member A6	Homo sapiens	18-22
12617235-8	2002	A number-needed-to-treat (NNT) analysis showed that, with MRSA prevalence at 15%, cefuroxime plus gentamicin at induction could prevent one MRSA infection per 421 treated patients compared with cefuroxime alone.	Gentamicins	98-108	solute carrier family 9 member A6	Homo sapiens	58-62
12617235-8	2002	A number-needed-to-treat (NNT) analysis showed that, with MRSA prevalence at 15%, cefuroxime plus gentamicin at induction could prevent one MRSA infection per 421 treated patients compared with cefuroxime alone.	Gentamicins	98-108	solute carrier family 9 member A6	Homo sapiens	140-144
12617235-7	2002	Gentamicin is active against more than 95% of MRSA strains cultured in our hospital and against 87% of MRSA strains cultured in the neurosurgery unit.	Gentamicins	0-10	solute carrier family 9 member A6	Homo sapiens	103-107
12617235-12	2002	Vancomycin can be reserved for patients known to be colonized with MRSA (NNT: 51).	Vancomycin	0-10	solute carrier family 9 member A6	Homo sapiens	67-71
12617235-8	2002	A number-needed-to-treat (NNT) analysis showed that, with MRSA prevalence at 15%, cefuroxime plus gentamicin at induction could prevent one MRSA infection per 421 treated patients compared with cefuroxime alone.	Cefuroxime	82-92	solute carrier family 9 member A6	Homo sapiens	58-62
12617235-8	2002	A number-needed-to-treat (NNT) analysis showed that, with MRSA prevalence at 15%, cefuroxime plus gentamicin at induction could prevent one MRSA infection per 421 treated patients compared with cefuroxime alone.	Cefuroxime	82-92	solute carrier family 9 member A6	Homo sapiens	140-144
11913373-0	2002	Incidence of pseudomembranous colitis after vancomycin-treated MRSA infection.	Vancomycin	44-54	solute carrier family 9 member A6	Homo sapiens	63-67
10452645-5	1999	In a multivariate linear regression model, rates of MRSA, central line-associated bloodstream infection, and the type of ICU were independent predictors of vancomycin use.	Vancomycin	156-166	solute carrier family 9 member A6	Homo sapiens	52-56
11828710-6	2001	Vancomycin or teicoplanin is selected when MRSA or Enterococcus faecium infection is suspected.	Vancomycin	0-10	solute carrier family 9 member A6	Homo sapiens	43-47
11828710-6	2001	Vancomycin or teicoplanin is selected when MRSA or Enterococcus faecium infection is suspected.	Teicoplanin	14-25	solute carrier family 9 member A6	Homo sapiens	43-47
11675980-8	2001	However, there is also reason for concern about the recent emergence of MRSA resistant to glycopeptides, such as vancomycin.	Glycopeptides	90-103	solute carrier family 9 member A6	Homo sapiens	72-76
11675980-8	2001	However, there is also reason for concern about the recent emergence of MRSA resistant to glycopeptides, such as vancomycin.	Vancomycin	113-123	solute carrier family 9 member A6	Homo sapiens	72-76
11357444-8	2001	The methicillin (oxacillin)-resistant S. aureus (MRSA, ORSA) stems usually present the phenomenon of multiresistance, i.e. the resistance towards substances of several classes of antibiotics, and, therefore, are not only resistant to all beta-lactamantibiotics (penicillins, cephalosporins, carbapenems).	Oxacillin	17-26	solute carrier family 9 member A6	Homo sapiens	49-53
11357444-8	2001	The methicillin (oxacillin)-resistant S. aureus (MRSA, ORSA) stems usually present the phenomenon of multiresistance, i.e. the resistance towards substances of several classes of antibiotics, and, therefore, are not only resistant to all beta-lactamantibiotics (penicillins, cephalosporins, carbapenems).	Monobactams	238-260	solute carrier family 9 member A6	Homo sapiens	49-53
11357444-8	2001	The methicillin (oxacillin)-resistant S. aureus (MRSA, ORSA) stems usually present the phenomenon of multiresistance, i.e. the resistance towards substances of several classes of antibiotics, and, therefore, are not only resistant to all beta-lactamantibiotics (penicillins, cephalosporins, carbapenems).	Penicillins	262-273	solute carrier family 9 member A6	Homo sapiens	49-53
11357444-8	2001	The methicillin (oxacillin)-resistant S. aureus (MRSA, ORSA) stems usually present the phenomenon of multiresistance, i.e. the resistance towards substances of several classes of antibiotics, and, therefore, are not only resistant to all beta-lactamantibiotics (penicillins, cephalosporins, carbapenems).	Cephalosporins	275-289	solute carrier family 9 member A6	Homo sapiens	49-53
11357444-8	2001	The methicillin (oxacillin)-resistant S. aureus (MRSA, ORSA) stems usually present the phenomenon of multiresistance, i.e. the resistance towards substances of several classes of antibiotics, and, therefore, are not only resistant to all beta-lactamantibiotics (penicillins, cephalosporins, carbapenems).	Carbapenems	291-302	solute carrier family 9 member A6	Homo sapiens	49-53
11249127-5	2001	Quinone methide 7 showed the most potent activity with 0.5-1 microg/mL of MIC against both MRSA and VRE.	quinone	0-7	solute carrier family 9 member A6	Homo sapiens	91-95
11249127-5	2001	Quinone methide 7 showed the most potent activity with 0.5-1 microg/mL of MIC against both MRSA and VRE.	methide 7	8-17	solute carrier family 9 member A6	Homo sapiens	91-95
11354818-4	2000	All the MRSA isolates in India including in the present study were sensitive to vancomycin and resistance to netilmycin appears to be low among MRSA isolates in India.	Vancomycin	80-90	solute carrier family 9 member A6	Homo sapiens	8-12
11354818-4	2000	All the MRSA isolates in India including in the present study were sensitive to vancomycin and resistance to netilmycin appears to be low among MRSA isolates in India.	Netilmicin	109-119	solute carrier family 9 member A6	Homo sapiens	8-12
11354818-4	2000	All the MRSA isolates in India including in the present study were sensitive to vancomycin and resistance to netilmycin appears to be low among MRSA isolates in India.	Netilmicin	109-119	solute carrier family 9 member A6	Homo sapiens	144-148
11354818-5	2000	All the MRSA isolates were also found to be sensitive to teicoplanin in the present study.	Teicoplanin	57-68	solute carrier family 9 member A6	Homo sapiens	8-12
11354818-6	2000	Like in other Indian studies, resistance to cotrimoxazole, erythromycin, gentamicin, other penicillins and cephalosporins appeared to be a common feature for MRSA isolates in the present study.	Trimethoprim, Sulfamethoxazole Drug Combination	44-57	solute carrier family 9 member A6	Homo sapiens	158-162
11354818-6	2000	Like in other Indian studies, resistance to cotrimoxazole, erythromycin, gentamicin, other penicillins and cephalosporins appeared to be a common feature for MRSA isolates in the present study.	Erythromycin	59-71	solute carrier family 9 member A6	Homo sapiens	158-162
11354818-6	2000	Like in other Indian studies, resistance to cotrimoxazole, erythromycin, gentamicin, other penicillins and cephalosporins appeared to be a common feature for MRSA isolates in the present study.	Gentamicins	73-83	solute carrier family 9 member A6	Homo sapiens	158-162
11354818-6	2000	Like in other Indian studies, resistance to cotrimoxazole, erythromycin, gentamicin, other penicillins and cephalosporins appeared to be a common feature for MRSA isolates in the present study.	Penicillins	91-102	solute carrier family 9 member A6	Homo sapiens	158-162
11354818-6	2000	Like in other Indian studies, resistance to cotrimoxazole, erythromycin, gentamicin, other penicillins and cephalosporins appeared to be a common feature for MRSA isolates in the present study.	Cephalosporins	107-121	solute carrier family 9 member A6	Homo sapiens	158-162
10998878-0	2000	[The influence of the use of mupirocin nasal ointment on the incidence of endogenous MRSA infections in an intensive care unit].	Mupirocin	29-38	solute carrier family 9 member A6	Homo sapiens	85-89
10998878-3	2000	To evaluate the impact of mupirocin use on the incidence of endogenous infection caused by MRSA in an intensive care unit, we prospectively treated all patients in the unit with mupirocin, 3 times daily for 3 days.	Mupirocin	26-35	solute carrier family 9 member A6	Homo sapiens	91-95
10998878-4	2000	This routine use of mupirocin led to eradication of nasal MRSA carriage in 81.8% of surveillance cultures and to a significant reduction in the total incidence of MRSA infection among MRSA carrier patients (0 episode in 11 patients) when compared to historical controls prior to the use of mupirocin (3 episodes in 7 patients).	Mupirocin	20-29	solute carrier family 9 member A6	Homo sapiens	58-62
10998878-4	2000	This routine use of mupirocin led to eradication of nasal MRSA carriage in 81.8% of surveillance cultures and to a significant reduction in the total incidence of MRSA infection among MRSA carrier patients (0 episode in 11 patients) when compared to historical controls prior to the use of mupirocin (3 episodes in 7 patients).	Mupirocin	20-29	solute carrier family 9 member A6	Homo sapiens	163-167
10998878-4	2000	This routine use of mupirocin led to eradication of nasal MRSA carriage in 81.8% of surveillance cultures and to a significant reduction in the total incidence of MRSA infection among MRSA carrier patients (0 episode in 11 patients) when compared to historical controls prior to the use of mupirocin (3 episodes in 7 patients).	Mupirocin	20-29	solute carrier family 9 member A6	Homo sapiens	163-167
10923284-8	2000	Vancomycin (VCM) and arbekacin (ABK) showed the most potent activities against MRSA.	Vancomycin	0-10	solute carrier family 9 member A6	Homo sapiens	79-83
10923284-8	2000	Vancomycin (VCM) and arbekacin (ABK) showed the most potent activities against MRSA.	Vancomycin	12-15	solute carrier family 9 member A6	Homo sapiens	79-83
10923284-8	2000	Vancomycin (VCM) and arbekacin (ABK) showed the most potent activities against MRSA.	arbekacin	21-30	solute carrier family 9 member A6	Homo sapiens	79-83
10522713-0	1999	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.	2-naphthylcarbapenems	0-21	solute carrier family 9 member A6	Homo sapiens	80-84
10565121-1	1999	Eleven clinical strains of MRSA which were detected as heterogeneously-resistant to vancomycin (hetero-VRSA) on Mu3-medium (a newly devised hetero-VRSA detecting medium) were subjected to a study to explore the therapeutic possibility of combination therapy.	Vancomycin	84-94	solute carrier family 9 member A6	Homo sapiens	27-31
10565121-1	1999	Eleven clinical strains of MRSA which were detected as heterogeneously-resistant to vancomycin (hetero-VRSA) on Mu3-medium (a newly devised hetero-VRSA detecting medium) were subjected to a study to explore the therapeutic possibility of combination therapy.	mu3-medium	112-122	solute carrier family 9 member A6	Homo sapiens	27-31
11357444-8	2001	The methicillin (oxacillin)-resistant S. aureus (MRSA, ORSA) stems usually present the phenomenon of multiresistance, i.e. the resistance towards substances of several classes of antibiotics, and, therefore, are not only resistant to all beta-lactamantibiotics (penicillins, cephalosporins, carbapenems).	Methicillin	4-15	solute carrier family 9 member A6	Homo sapiens	49-53
11249127-0	2001	Synthesis of variously oxidized abietane diterpenes and their antibacterial activities against MRSA and VRE.	Abietanes	32-40	solute carrier family 9 member A6	Homo sapiens	95-99
11249127-0	2001	Synthesis of variously oxidized abietane diterpenes and their antibacterial activities against MRSA and VRE.	Diterpenes	41-51	solute carrier family 9 member A6	Homo sapiens	95-99
11249127-2	2001	Antimicrobial activities of synthesized phenolic diterpenes and their related compounds against MRSA and VRE were evaluated.	Diterpenes	49-59	solute carrier family 9 member A6	Homo sapiens	96-100
11249127-3	2001	Phenols (12-hydroxyabieta-8,11,13-trien-6-one 22 and 23), catechols (12 and 14) and taxodione 25 showed potent activity with 4-10 microg/mL of MIC against MRSA and 4-16 microg/mL of MIC against VRE.	Phenols	0-7	solute carrier family 9 member A6	Homo sapiens	155-159
11249127-3	2001	Phenols (12-hydroxyabieta-8,11,13-trien-6-one 22 and 23), catechols (12 and 14) and taxodione 25 showed potent activity with 4-10 microg/mL of MIC against MRSA and 4-16 microg/mL of MIC against VRE.	12-hydroxyabieta-8,11,13-trien-6-one	9-45	solute carrier family 9 member A6	Homo sapiens	155-159
11249127-3	2001	Phenols (12-hydroxyabieta-8,11,13-trien-6-one 22 and 23), catechols (12 and 14) and taxodione 25 showed potent activity with 4-10 microg/mL of MIC against MRSA and 4-16 microg/mL of MIC against VRE.	taxodione	84-93	solute carrier family 9 member A6	Homo sapiens	155-159
11206444-0	2001	New anti-MRSA cephalosporins with a basic aminopyridine at the C-7 position.	Cephalosporins	14-28	solute carrier family 9 member A6	Homo sapiens	9-13
11206444-0	2001	New anti-MRSA cephalosporins with a basic aminopyridine at the C-7 position.	basic aminopyridine	36-55	solute carrier family 9 member A6	Homo sapiens	9-13
11206444-1	2001	Incorporation of a basic aminopyridine into the C-7 position of 3-(amine-substituted arylthio)-3-norcephalosporins, as in 3, afforded high potency against MRSA and acceptable solubility for intravenous administration.	basic aminopyridine	19-38	solute carrier family 9 member A6	Homo sapiens	155-159
11206444-1	2001	Incorporation of a basic aminopyridine into the C-7 position of 3-(amine-substituted arylthio)-3-norcephalosporins, as in 3, afforded high potency against MRSA and acceptable solubility for intravenous administration.	3-(amine-substituted arylthio)-3-norcephalosporins	64-114	solute carrier family 9 member A6	Homo sapiens	155-159
11234220-0	2000	[Combination effect of teicoplanin and beta-lactams on MRSA].	Teicoplanin	23-34	solute carrier family 9 member A6	Homo sapiens	55-60
11234220-0	2000	[Combination effect of teicoplanin and beta-lactams on MRSA].	beta-Lactams	39-51	solute carrier family 9 member A6	Homo sapiens	55-60
11144420-5	2000	The overall frequency of drug resistance traits among the 1,749 MRSA strains was high (over 70% and up to and over 90% of the strains) to ciprofloxacin, erythromycin, clindamycin, gentamicin, and tetracycline, and was somewhat less frequent to sulfamethoxazole-trimethoprim (45%), chloramphenicol (30%), and rifampin (38%).	Ciprofloxacin	138-151	solute carrier family 9 member A6	Homo sapiens	64-68
11144420-5	2000	The overall frequency of drug resistance traits among the 1,749 MRSA strains was high (over 70% and up to and over 90% of the strains) to ciprofloxacin, erythromycin, clindamycin, gentamicin, and tetracycline, and was somewhat less frequent to sulfamethoxazole-trimethoprim (45%), chloramphenicol (30%), and rifampin (38%).	Erythromycin	153-165	solute carrier family 9 member A6	Homo sapiens	64-68
11144420-5	2000	The overall frequency of drug resistance traits among the 1,749 MRSA strains was high (over 70% and up to and over 90% of the strains) to ciprofloxacin, erythromycin, clindamycin, gentamicin, and tetracycline, and was somewhat less frequent to sulfamethoxazole-trimethoprim (45%), chloramphenicol (30%), and rifampin (38%).	Clindamycin	167-178	solute carrier family 9 member A6	Homo sapiens	64-68
11144420-5	2000	The overall frequency of drug resistance traits among the 1,749 MRSA strains was high (over 70% and up to and over 90% of the strains) to ciprofloxacin, erythromycin, clindamycin, gentamicin, and tetracycline, and was somewhat less frequent to sulfamethoxazole-trimethoprim (45%), chloramphenicol (30%), and rifampin (38%).	Gentamicins	180-190	solute carrier family 9 member A6	Homo sapiens	64-68
11144420-5	2000	The overall frequency of drug resistance traits among the 1,749 MRSA strains was high (over 70% and up to and over 90% of the strains) to ciprofloxacin, erythromycin, clindamycin, gentamicin, and tetracycline, and was somewhat less frequent to sulfamethoxazole-trimethoprim (45%), chloramphenicol (30%), and rifampin (38%).	Tetracycline	196-208	solute carrier family 9 member A6	Homo sapiens	64-68
11144420-5	2000	The overall frequency of drug resistance traits among the 1,749 MRSA strains was high (over 70% and up to and over 90% of the strains) to ciprofloxacin, erythromycin, clindamycin, gentamicin, and tetracycline, and was somewhat less frequent to sulfamethoxazole-trimethoprim (45%), chloramphenicol (30%), and rifampin (38%).	Trimethoprim, Sulfamethoxazole Drug Combination	244-273	solute carrier family 9 member A6	Homo sapiens	64-68
11144420-5	2000	The overall frequency of drug resistance traits among the 1,749 MRSA strains was high (over 70% and up to and over 90% of the strains) to ciprofloxacin, erythromycin, clindamycin, gentamicin, and tetracycline, and was somewhat less frequent to sulfamethoxazole-trimethoprim (45%), chloramphenicol (30%), and rifampin (38%).	Chloramphenicol	281-296	solute carrier family 9 member A6	Homo sapiens	64-68
11144420-5	2000	The overall frequency of drug resistance traits among the 1,749 MRSA strains was high (over 70% and up to and over 90% of the strains) to ciprofloxacin, erythromycin, clindamycin, gentamicin, and tetracycline, and was somewhat less frequent to sulfamethoxazole-trimethoprim (45%), chloramphenicol (30%), and rifampin (38%).	Rifampin	308-316	solute carrier family 9 member A6	Homo sapiens	64-68
10998878-5	2000	Mupirocin nasal ointment was significantly effective to prevent endogenous MRSA infection.	Mupirocin	0-9	solute carrier family 9 member A6	Homo sapiens	75-79
10631792-0	1999	Eradication of MRSA from carriers by means of whole-body washing with an antiseptic in combination with mupirocin nasal ointment.	Mupirocin	104-113	solute carrier family 9 member A6	Homo sapiens	15-19
10631792-10	1999	The study confirms that MRSA can be eradicated by means of washing with an antiseptic combined with mupirocin treatment.	Mupirocin	100-109	solute carrier family 9 member A6	Homo sapiens	24-28
10563691-1	1999	Rifampicin has been successfully used as an adjunct to vancomycin therapy in several clinical conditions of MRSA infections such as endocarditis, ventriculoperitoneal shunts and septicaemia.	Rifampin	0-10	solute carrier family 9 member A6	Homo sapiens	108-112
10563691-1	1999	Rifampicin has been successfully used as an adjunct to vancomycin therapy in several clinical conditions of MRSA infections such as endocarditis, ventriculoperitoneal shunts and septicaemia.	Vancomycin	55-65	solute carrier family 9 member A6	Homo sapiens	108-112
10563691-3	1999	The present prospective study was conducted to evaluate the efficacy of rifampicin as an adjunct therapy in burn cases with MRSA septicaemia not responding well to vancomycin.	Rifampin	72-82	solute carrier family 9 member A6	Homo sapiens	124-128
10563691-11	1999	Institution of rifampicin, as an adjunct to vancomycin therapy to which the MRSA isolates were susceptible, showed a dramatic clinical response and survival of grafts.	Rifampin	15-25	solute carrier family 9 member A6	Homo sapiens	76-80
10563691-11	1999	Institution of rifampicin, as an adjunct to vancomycin therapy to which the MRSA isolates were susceptible, showed a dramatic clinical response and survival of grafts.	Vancomycin	44-54	solute carrier family 9 member A6	Homo sapiens	76-80
10563691-13	1999	The present study thus confirms the efficacy of clinical use of rifampicin as an adjunct in vancomycin nonresponding cases of MRSA septicaemia in burns.	Rifampin	64-74	solute carrier family 9 member A6	Homo sapiens	126-130
10565121-11	1999	It is known that MRSA is relatively easy to emerge resistance to teicoplanin.	Teicoplanin	65-76	solute carrier family 9 member A6	Homo sapiens	17-21
10565121-13	1999	However, in a combination with beta-lactam antibiotics, teicoplanin appeared to be a promising agent for the treatment of MRSA infection.	Teicoplanin	56-67	solute carrier family 9 member A6	Homo sapiens	122-126
10423963-3	1999	As the control of bacteria and the surgical intervention are both important in the treatment of pyothorax cases, we tried to reduce MRSA by washing with Povidone-Iodine solution through the drain.	Povidone-Iodine	153-168	solute carrier family 9 member A6	Homo sapiens	132-136
10423963-6	1999	During the operation we frequently used acidic electrolyzed NaCl solution against MRSA.	nacl solution	60-73	solute carrier family 9 member A6	Homo sapiens	82-86
10423963-7	1999	For one month after the operation, we used Vancomycin which is effective against MRSA, however, rather severe side effects were seen, and finally and MRSA vanished.	Vancomycin	43-53	solute carrier family 9 member A6	Homo sapiens	81-85
10423963-7	1999	For one month after the operation, we used Vancomycin which is effective against MRSA, however, rather severe side effects were seen, and finally and MRSA vanished.	Vancomycin	43-53	solute carrier family 9 member A6	Homo sapiens	150-154
10452645-7	1999	Vancomycin use is heavily determined by rates of endemic MRSA and central line-associated bloodstream infection.	Vancomycin	0-10	solute carrier family 9 member A6	Homo sapiens	57-61
10326611-0	1999	New cases of vancomycin-intermediate MRSA infection reported.	Vancomycin	13-23	solute carrier family 9 member A6	Homo sapiens	37-41
10063475-1	1999	We investigated the use of tube coagulase and a fluorescent substrate, N-t-BOC-val-pro-arg-7-amido-4-methylcoumarin for the rapid detection of MRSA in selective broth enrichment cultures during an outbreak.	n-t-boc-val-pro-arg-7-amido-4-methylcoumarin	71-115	solute carrier family 9 member A6	Homo sapiens	143-147
9852643-1	1998	OBJECTIVES: To identify the attributed mortality rate of bloodstream hospital infection by Staphylococcus aureus resistant to methicillin (MRSA) and its effect on length of hospital stay.	Methicillin	126-137	solute carrier family 9 member A6	Homo sapiens	139-143
10481526-7	1999	We suggest that local administration of vancomycin is an effective method in postpneumonectomy empyema with MRSA infection.	Vancomycin	40-50	solute carrier family 9 member A6	Homo sapiens	108-112
9818969-3	1998	The I:E:F clonal type and a stable drug multidrug resistant phenotype (sensitivity only to trimethoprim/sulfamethoxazole and vancomycin) indicated that these isolates were closely related to the Iberian clone of MRSA, which is widely spread in Europe.	Trimethoprim, Sulfamethoxazole Drug Combination	91-120	solute carrier family 9 member A6	Homo sapiens	212-216
9818969-3	1998	The I:E:F clonal type and a stable drug multidrug resistant phenotype (sensitivity only to trimethoprim/sulfamethoxazole and vancomycin) indicated that these isolates were closely related to the Iberian clone of MRSA, which is widely spread in Europe.	Vancomycin	125-135	solute carrier family 9 member A6	Homo sapiens	212-216
9789363-10	1998	MRSA-strains were more resistant to imipenem, ofloxacin, gentamicin, trimethoprim-sulfamethoxazole, tetracycline, erythromycin and clindamycin as oxacillin-sensitive Straphylococcus aureus strains.	Imipenem	36-44	solute carrier family 9 member A6	Homo sapiens	0-4
9789363-10	1998	MRSA-strains were more resistant to imipenem, ofloxacin, gentamicin, trimethoprim-sulfamethoxazole, tetracycline, erythromycin and clindamycin as oxacillin-sensitive Straphylococcus aureus strains.	Ofloxacin	46-55	solute carrier family 9 member A6	Homo sapiens	0-4
9789363-10	1998	MRSA-strains were more resistant to imipenem, ofloxacin, gentamicin, trimethoprim-sulfamethoxazole, tetracycline, erythromycin and clindamycin as oxacillin-sensitive Straphylococcus aureus strains.	Gentamicins	57-67	solute carrier family 9 member A6	Homo sapiens	0-4
9789363-10	1998	MRSA-strains were more resistant to imipenem, ofloxacin, gentamicin, trimethoprim-sulfamethoxazole, tetracycline, erythromycin and clindamycin as oxacillin-sensitive Straphylococcus aureus strains.	Trimethoprim, Sulfamethoxazole Drug Combination	69-98	solute carrier family 9 member A6	Homo sapiens	0-4
9789363-10	1998	MRSA-strains were more resistant to imipenem, ofloxacin, gentamicin, trimethoprim-sulfamethoxazole, tetracycline, erythromycin and clindamycin as oxacillin-sensitive Straphylococcus aureus strains.	Tetracycline	100-112	solute carrier family 9 member A6	Homo sapiens	0-4
9789363-10	1998	MRSA-strains were more resistant to imipenem, ofloxacin, gentamicin, trimethoprim-sulfamethoxazole, tetracycline, erythromycin and clindamycin as oxacillin-sensitive Straphylococcus aureus strains.	Erythromycin	114-126	solute carrier family 9 member A6	Homo sapiens	0-4
9789363-10	1998	MRSA-strains were more resistant to imipenem, ofloxacin, gentamicin, trimethoprim-sulfamethoxazole, tetracycline, erythromycin and clindamycin as oxacillin-sensitive Straphylococcus aureus strains.	Clindamycin	131-142	solute carrier family 9 member A6	Homo sapiens	0-4
9789363-10	1998	MRSA-strains were more resistant to imipenem, ofloxacin, gentamicin, trimethoprim-sulfamethoxazole, tetracycline, erythromycin and clindamycin as oxacillin-sensitive Straphylococcus aureus strains.	Oxacillin	146-155	solute carrier family 9 member A6	Homo sapiens	0-4
12631818-1	1997	Strains of Staphylococcus aureusresistant to multiple antibiotics, including those resistant to methicillin (MRSA), present a major problem in the control of hospital acquired infections.	Methicillin	96-107	solute carrier family 9 member A6	Homo sapiens	109-113
10681822-1	1998	MRSA and MRSE were identified by detecting oxacillin resistance of 107 strains of staphylococci from clinical sources.	Oxacillin	43-52	solute carrier family 9 member A6	Homo sapiens	0-4
9373559-5	1997	Once MRSA had been identified they were treated with intravenous teicoplanin and all made a full recovery.	Teicoplanin	65-76	solute carrier family 9 member A6	Homo sapiens	5-9
9259029-5	1997	In most Western countries with a relatively low incidence of MRSA, penicillin-derivatives, such as flucloxacillin (or cloxacillin, methicillin and nafcillin) will be the drug of choice, because of their good in-vitro activity, low toxicity, good clinical efficacy and relatively low cost.	Penicillins	67-77	solute carrier family 9 member A6	Homo sapiens	61-65
9259029-5	1997	In most Western countries with a relatively low incidence of MRSA, penicillin-derivatives, such as flucloxacillin (or cloxacillin, methicillin and nafcillin) will be the drug of choice, because of their good in-vitro activity, low toxicity, good clinical efficacy and relatively low cost.	Floxacillin	99-113	solute carrier family 9 member A6	Homo sapiens	61-65
9259029-5	1997	In most Western countries with a relatively low incidence of MRSA, penicillin-derivatives, such as flucloxacillin (or cloxacillin, methicillin and nafcillin) will be the drug of choice, because of their good in-vitro activity, low toxicity, good clinical efficacy and relatively low cost.	Cloxacillin	102-113	solute carrier family 9 member A6	Homo sapiens	61-65
9259029-5	1997	In most Western countries with a relatively low incidence of MRSA, penicillin-derivatives, such as flucloxacillin (or cloxacillin, methicillin and nafcillin) will be the drug of choice, because of their good in-vitro activity, low toxicity, good clinical efficacy and relatively low cost.	Methicillin	131-142	solute carrier family 9 member A6	Homo sapiens	61-65
9259029-5	1997	In most Western countries with a relatively low incidence of MRSA, penicillin-derivatives, such as flucloxacillin (or cloxacillin, methicillin and nafcillin) will be the drug of choice, because of their good in-vitro activity, low toxicity, good clinical efficacy and relatively low cost.	Nafcillin	147-156	solute carrier family 9 member A6	Homo sapiens	61-65
9259029-6	1997	If the incidence of MRSA increases, drugs such as the glycopeptides will be of more importance.	Glycopeptides	54-67	solute carrier family 9 member A6	Homo sapiens	20-24
8724815-2	1996	For example, there has been a sharp increase in the incidence of infections caused by Staphylococcus aureus, particularly those resistant to methicillin (MRSA), and methicillin-resistant coagulase-negative staphylococci, particularly those associated with foreign bodies and indwelling medical devices.	Methicillin	141-152	solute carrier family 9 member A6	Homo sapiens	154-158
9192247-0	1997	[Effect of imipenem/cilastatin combined with vancomycin for MRSA infection].	Imipenem	11-19	solute carrier family 9 member A6	Homo sapiens	60-64
9192247-0	1997	[Effect of imipenem/cilastatin combined with vancomycin for MRSA infection].	Cilastatin	20-30	solute carrier family 9 member A6	Homo sapiens	60-64
9192247-0	1997	[Effect of imipenem/cilastatin combined with vancomycin for MRSA infection].	Vancomycin	45-55	solute carrier family 9 member A6	Homo sapiens	60-64
9192247-6	1997	The present results suggested that simultaneous use of IPM/CS and VCM at the standard doses could yield an enhancement of both bacteriological and clinical efficacies in treatment of the patients with MRSA infection.	Cesium	59-61	solute carrier family 9 member A6	Homo sapiens	201-205
9594292-0	1997	Multiple antibiotic-resistant lactic acid bacteria preparation eliminated MRSA from the decubitus of a bed-ridden elderly patient.	Lactic Acid	30-41	solute carrier family 9 member A6	Homo sapiens	74-78
9053533-0	1996	[Clinical studies on vancomycin in the treatment of MRSA infection].	Vancomycin	21-31	solute carrier family 9 member A6	Homo sapiens	52-56
9053533-7	1996	(1) In cases of single infection with MRSA, the rate of bacterial eradication was 71.4% (5/7) with VCM alone and 68.2% (30/44) with VCM in combination with beta-lactam antibiotics.	beta-Lactams	156-167	solute carrier family 9 member A6	Homo sapiens	38-42
8752859-0	1996	[Management of MRSA-harboring patients: focused on mupirocin].	Mupirocin	51-60	solute carrier family 9 member A6	Homo sapiens	15-19
8072164-0	1994	[Special issue: Current state of MRSA infections and practical chemotherapy with arbekacin].	arbekacin	81-90	solute carrier family 9 member A6	Homo sapiens	33-37
7807691-2	1994	We conducted a multicenter trial to determine the clinical usefulness of the combined therapy with flomoxef (FMOX) and fosfomycin (FOM) (FF therapy) as an empirical therapy in the treatment of intractable respiratory tract infections, because FF therapy has clinically been proved to be very useful for the treatment of severe infections including MRSA infections.	flomoxef	99-107	solute carrier family 9 member A6	Homo sapiens	348-352
7807691-2	1994	We conducted a multicenter trial to determine the clinical usefulness of the combined therapy with flomoxef (FMOX) and fosfomycin (FOM) (FF therapy) as an empirical therapy in the treatment of intractable respiratory tract infections, because FF therapy has clinically been proved to be very useful for the treatment of severe infections including MRSA infections.	Fosfomycin	131-134	solute carrier family 9 member A6	Homo sapiens	348-352
8072168-18	1994	MRSA has become more resistant to methicillin however it seemed to have become less toxic.	Methicillin	34-45	solute carrier family 9 member A6	Homo sapiens	0-4
8072181-0	1994	[Clinical efficacy of arbekacin on MRSA infections].	arbekacin	22-31	solute carrier family 9 member A6	Homo sapiens	35-39
8072181-1	1994	Clinical efficacy of arbekacin (ABK) was examined on patients with MRSA infection during hospitalization in Nagoya University Hospital.	arbekacin	21-30	solute carrier family 9 member A6	Homo sapiens	67-71
8072182-1	1994	Niigata Research Group of MRSA.ABK].	niigata	0-7	solute carrier family 9 member A6	Homo sapiens	26-30
8072182-6	1994	These results are comparable with, or superior to the vancomycin therapy in the treatment of MRSA pneumonia.	Vancomycin	54-64	solute carrier family 9 member A6	Homo sapiens	93-97
7791423-6	1995	Minocycline is the preferred drug for MRSA colonization/infection.	Minocycline	0-11	solute carrier family 9 member A6	Homo sapiens	38-42
8549296-0	1995	Analysis of quinolone resistance genes in a clinical isolate of quinolone-resistant MRSA.	Quinolones	12-21	solute carrier family 9 member A6	Homo sapiens	84-88
8549296-0	1995	Analysis of quinolone resistance genes in a clinical isolate of quinolone-resistant MRSA.	Quinolones	64-73	solute carrier family 9 member A6	Homo sapiens	84-88
7806873-0	1994	Mupirocin-resistant MRSA.	Mupirocin	0-9	solute carrier family 9 member A6	Homo sapiens	20-24
8151141-5	1994	Administration of antibiotics before isolation of Staphylococcus aureus were thought to be the most significant factor in producing the methicillin-resistant septicemia, used in 41% of MSSA and 91.3% of MRSA cases.	Methicillin	136-147	solute carrier family 9 member A6	Homo sapiens	203-207
8129380-6	1994	For treatment of MRSA infections in patients with malignancy, a combination chemotherapy with vancomycin (VCM), or arbekacin (ABK) plus beta-lactam antibiotic is recommended, and granulocyte colony stimulating factor (G-CSF) is clinically useful when the granulocytopenia was induced by chemotherapy.	Vancomycin	94-104	solute carrier family 9 member A6	Homo sapiens	17-21
8072185-0	1994	[Clinical efficacy of arbekacin on MRSA infections with hematopoietic disorders.	arbekacin	22-31	solute carrier family 9 member A6	Homo sapiens	35-39
8072185-2	1994	Arbekacin (ABK) was administered to 17 patients with MRSA infections that complicated underlying hematopoietic disorders, and the efficacy and safety were evaluated.	arbekacin	0-9	solute carrier family 9 member A6	Homo sapiens	53-57
8072185-11	1994	Arbekacin therapy was found to be effective even in patients with hematopoietic disorders accompanied by MRSA infections.	arbekacin	0-9	solute carrier family 9 member A6	Homo sapiens	105-109
8072194-0	1994	[Clinical effect of arbekacin on MRSA infections after gastrointestinal surgery].	arbekacin	20-29	solute carrier family 9 member A6	Homo sapiens	33-37
8282584-0	1993	[Detection of MRSA in National Leprosarium of Ohshima Seisho-En].	ohshima seisho-en	46-63	solute carrier family 9 member A6	Homo sapiens	14-18
8195837-3	1993	The incidence of trimethoprim resistance is highly variable, depending upon methodology, type of patients, local epidemiology: this can be illustrated by the high variation of trimethoprim resistance among Salmonella, Shigella or MRSA in various countries and by the incidence of resistance in penicillin-resistant Streptococcus pneumoniae.	Trimethoprim	17-29	solute carrier family 9 member A6	Homo sapiens	230-234
8195837-3	1993	The incidence of trimethoprim resistance is highly variable, depending upon methodology, type of patients, local epidemiology: this can be illustrated by the high variation of trimethoprim resistance among Salmonella, Shigella or MRSA in various countries and by the incidence of resistance in penicillin-resistant Streptococcus pneumoniae.	Trimethoprim	176-188	solute carrier family 9 member A6	Homo sapiens	230-234
1293220-9	1992	Concerning the drug sensitivity, many MRSA strains were highly resistant to DMPPC and FOM, but the sensitivity to RFP was 0.1 microgram/ml or less in all strains except for one highly resistant strain (200 micrograms/ml or above).	dmppc	76-81	solute carrier family 9 member A6	Homo sapiens	38-42
8320471-0	1993	[MICs of oxacillin for MRSA: a comparative study of strains from staff and patients].	Oxacillin	9-18	solute carrier family 9 member A6	Homo sapiens	23-27
8290904-6	1993	Virtually any agent will select MRSA and MRSE since the chromosomal location of the resistance of multiple-antibiotics makes such selection common and explains the rapid rate of the fluoroquinolones as therapy of MRSA.	Fluoroquinolones	182-198	solute carrier family 9 member A6	Homo sapiens	32-36
8290904-6	1993	Virtually any agent will select MRSA and MRSE since the chromosomal location of the resistance of multiple-antibiotics makes such selection common and explains the rapid rate of the fluoroquinolones as therapy of MRSA.	Fluoroquinolones	182-198	solute carrier family 9 member A6	Homo sapiens	213-217
1863618-10	1991	Our MRSA strain belong to phage type III, and shows a characteristic multiple antibiotic resistant pattern, the MRSA strain is sensitive to vancomycin, fusidic acid, phosphomycin and cotrimoxazole.	Vancomycin	140-150	solute carrier family 9 member A6	Homo sapiens	4-8
1863618-10	1991	Our MRSA strain belong to phage type III, and shows a characteristic multiple antibiotic resistant pattern, the MRSA strain is sensitive to vancomycin, fusidic acid, phosphomycin and cotrimoxazole.	Vancomycin	140-150	solute carrier family 9 member A6	Homo sapiens	112-116
1863618-10	1991	Our MRSA strain belong to phage type III, and shows a characteristic multiple antibiotic resistant pattern, the MRSA strain is sensitive to vancomycin, fusidic acid, phosphomycin and cotrimoxazole.	Fusidic Acid	152-164	solute carrier family 9 member A6	Homo sapiens	4-8
1863618-10	1991	Our MRSA strain belong to phage type III, and shows a characteristic multiple antibiotic resistant pattern, the MRSA strain is sensitive to vancomycin, fusidic acid, phosphomycin and cotrimoxazole.	Fusidic Acid	152-164	solute carrier family 9 member A6	Homo sapiens	112-116
1863618-10	1991	Our MRSA strain belong to phage type III, and shows a characteristic multiple antibiotic resistant pattern, the MRSA strain is sensitive to vancomycin, fusidic acid, phosphomycin and cotrimoxazole.	Fosfomycin	166-178	solute carrier family 9 member A6	Homo sapiens	4-8
1863618-10	1991	Our MRSA strain belong to phage type III, and shows a characteristic multiple antibiotic resistant pattern, the MRSA strain is sensitive to vancomycin, fusidic acid, phosphomycin and cotrimoxazole.	Fosfomycin	166-178	solute carrier family 9 member A6	Homo sapiens	112-116
1863618-10	1991	Our MRSA strain belong to phage type III, and shows a characteristic multiple antibiotic resistant pattern, the MRSA strain is sensitive to vancomycin, fusidic acid, phosphomycin and cotrimoxazole.	Trimethoprim, Sulfamethoxazole Drug Combination	183-196	solute carrier family 9 member A6	Homo sapiens	4-8
1863618-10	1991	Our MRSA strain belong to phage type III, and shows a characteristic multiple antibiotic resistant pattern, the MRSA strain is sensitive to vancomycin, fusidic acid, phosphomycin and cotrimoxazole.	Trimethoprim, Sulfamethoxazole Drug Combination	183-196	solute carrier family 9 member A6	Homo sapiens	112-116
1863618-11	1991	Over the entire outbreak period, the MRSA strain developed resistance to rifampin, imipenem-cilastatin and ciprofloxacin.	Rifampin	73-81	solute carrier family 9 member A6	Homo sapiens	37-41
1863618-11	1991	Over the entire outbreak period, the MRSA strain developed resistance to rifampin, imipenem-cilastatin and ciprofloxacin.	Cilastatin, Imipenem Drug Combination	83-102	solute carrier family 9 member A6	Homo sapiens	37-41
1863618-11	1991	Over the entire outbreak period, the MRSA strain developed resistance to rifampin, imipenem-cilastatin and ciprofloxacin.	Ciprofloxacin	107-120	solute carrier family 9 member A6	Homo sapiens	37-41
2233663-0	1990	[Intravenous administration of vancomycin for postoperative MRSA infection and its pharmacokinetics: preliminary report].	Vancomycin	31-41	solute carrier family 9 member A6	Homo sapiens	60-64
1507428-3	1992	Arbekacin, a newly developed aminoglycoside antibiotic, showed more active than vancomycin to MRSA in vitro.	arbekacin	0-9	solute carrier family 9 member A6	Homo sapiens	94-98
1507428-3	1992	Arbekacin, a newly developed aminoglycoside antibiotic, showed more active than vancomycin to MRSA in vitro.	Vancomycin	80-90	solute carrier family 9 member A6	Homo sapiens	94-98
1507428-5	1992	Combined activity of arbekacin and vancomycin against 27 MRSA strains was evaluated by checkerboard technique.	arbekacin	21-30	solute carrier family 9 member A6	Homo sapiens	57-61
1507428-5	1992	Combined activity of arbekacin and vancomycin against 27 MRSA strains was evaluated by checkerboard technique.	Vancomycin	35-45	solute carrier family 9 member A6	Homo sapiens	57-61
1507434-5	1992	In a postoperative multiple trauma patient, with pneumonia, thoracic empyema, intraabdominal abscess, wound infection and sepsis caused by MRSA, surgical drainage of the abscess with systemic infusion of vancomycin was effective and resulted in full recovery.	Vancomycin	204-214	solute carrier family 9 member A6	Homo sapiens	139-143
1507441-3	1992	Factors contributing to MRSA infections were mainly indwelling catheterization, preceding antimicrobial therapy (new quinolones and new cephems), and obstructive disease.	Quinolones	117-127	solute carrier family 9 member A6	Homo sapiens	24-28
1507441-3	1992	Factors contributing to MRSA infections were mainly indwelling catheterization, preceding antimicrobial therapy (new quinolones and new cephems), and obstructive disease.	cephems	136-143	solute carrier family 9 member A6	Homo sapiens	24-28
1507452-8	1992	As for drug susceptibility, MRSA strains with coagulase type VII were more sensitive to clindamycin and more resistant to minocyclin compared to MRSA with other coagulase types.	Clindamycin	88-99	solute carrier family 9 member A6	Homo sapiens	28-32